US20030203976A1
(en)
|
1993-07-19 |
2003-10-30 |
William L. Hunter |
Anti-angiogenic compositions and methods of use
|
ES2290074T3
(es)
|
1993-07-19 |
2008-02-16 |
Angiotech Pharmaceuticals, Inc. |
Composiciones anti-angiogenicas que contienen taxol y un vehiculo no biodegradable y su uso.
|
KR100361933B1
(ko)
*
|
1993-09-08 |
2003-02-14 |
라 졸라 파마슈티칼 컴파니 |
화학적으로정의된비중합성결합가플랫폼분자및그것의콘주게이트
|
US5919455A
(en)
*
|
1993-10-27 |
1999-07-06 |
Enzon, Inc. |
Non-antigenic branched polymer conjugates
|
US5730990A
(en)
*
|
1994-06-24 |
1998-03-24 |
Enzon, Inc. |
Non-antigenic amine derived polymers and polymer conjugates
|
US7820798B2
(en)
*
|
1994-11-07 |
2010-10-26 |
Human Genome Sciences, Inc. |
Tumor necrosis factor-gamma
|
US7597886B2
(en)
*
|
1994-11-07 |
2009-10-06 |
Human Genome Sciences, Inc. |
Tumor necrosis factor-gamma
|
US5932462A
(en)
|
1995-01-10 |
1999-08-03 |
Shearwater Polymers, Inc. |
Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
|
US7429646B1
(en)
|
1995-06-05 |
2008-09-30 |
Human Genome Sciences, Inc. |
Antibodies to human tumor necrosis factor receptor-like 2
|
DE741187T1
(de)
*
|
1995-05-05 |
1997-04-30 |
Hoffmann La Roche |
Rekombinante Obesitäts-(OB)-Proteine
|
ZA963530B
(en)
*
|
1995-05-05 |
1996-11-05 |
Hoffmann La Roche |
Recombinant obese (ob) proteins
|
US7048906B2
(en)
|
1995-05-17 |
2006-05-23 |
Cedars-Sinai Medical Center |
Methods of diagnosing and treating small intestinal bacterial overgrowth (SIBO) and SIBO-related conditions
|
US6833408B2
(en)
|
1995-12-18 |
2004-12-21 |
Cohesion Technologies, Inc. |
Methods for tissue repair using adhesive materials
|
DK1704878T3
(da)
|
1995-12-18 |
2013-07-01 |
Angiodevice Internat Gmbh |
Tværbundne polymerpræparater og fremgangsmåder til deres anvendelse
|
US6458889B1
(en)
|
1995-12-18 |
2002-10-01 |
Cohesion Technologies, Inc. |
Compositions and systems for forming crosslinked biomaterials and associated methods of preparation and use
|
US7883693B2
(en)
|
1995-12-18 |
2011-02-08 |
Angiodevice International Gmbh |
Compositions and systems for forming crosslinked biomaterials and methods of preparation of use
|
US7888466B2
(en)
|
1996-01-11 |
2011-02-15 |
Human Genome Sciences, Inc. |
Human G-protein chemokine receptor HSATU68
|
US6713061B1
(en)
|
1996-03-12 |
2004-03-30 |
Human Genome Sciences, Inc. |
Death domain containing receptors
|
JP3737518B2
(ja)
*
|
1996-03-12 |
2006-01-18 |
ピージー−ティーエックスエル カンパニー, エル.ピー. |
水溶性パクリタキセルプロドラッグ
|
US7357927B2
(en)
*
|
1996-03-12 |
2008-04-15 |
Human Genome Sciences, Inc. |
Death domain containing receptors
|
US6441025B2
(en)
|
1996-03-12 |
2002-08-27 |
Pg-Txl Company, L.P. |
Water soluble paclitaxel derivatives
|
WO1997033904A1
(en)
|
1996-03-12 |
1997-09-18 |
Human Genome Sciences, Inc. |
Death domain containing receptors
|
US6635743B1
(en)
|
1996-03-22 |
2003-10-21 |
Human Genome Sciences, Inc. |
Apoptosis inducing molecule II and methods of use
|
US7964190B2
(en)
*
|
1996-03-22 |
2011-06-21 |
Human Genome Sciences, Inc. |
Methods and compositions for decreasing T-cell activity
|
US6025324A
(en)
*
|
1996-05-15 |
2000-02-15 |
Hoffmann-La Roche Inc. |
Pegylated obese (ob) protein compositions
|
TW517067B
(en)
*
|
1996-05-31 |
2003-01-11 |
Hoffmann La Roche |
Interferon conjugates
|
IL128229A0
(en)
*
|
1996-08-02 |
1999-11-30 |
Ortho Mcneil Pharm Inc |
Polypeptides having a single covalently bound n-terminal water-soluble polymer
|
US6214966B1
(en)
|
1996-09-26 |
2001-04-10 |
Shearwater Corporation |
Soluble, degradable poly(ethylene glycol) derivatives for controllable release of bound molecules into solution
|
US6812327B1
(en)
*
|
1996-10-25 |
2004-11-02 |
Human Genome Sciences, Inc. |
Neutrokine-alpha polypeptides
|
US8212004B2
(en)
*
|
1999-03-02 |
2012-07-03 |
Human Genome Sciences, Inc. |
Neutrokine-alpha fusion proteins
|
IL131406A0
(en)
|
1997-02-21 |
2001-01-28 |
Genentech Inc |
Antibody fragment-polymer conjugates and humanized anti-il-8 monoclonal antibodies
|
US7122636B1
(en)
|
1997-02-21 |
2006-10-17 |
Genentech, Inc. |
Antibody fragment-polymer conjugates and uses of same
|
US20050233958A1
(en)
*
|
1997-03-17 |
2005-10-20 |
Human Genome Sciences, Inc. |
Death domain containing receptor 5
|
US20040136951A1
(en)
*
|
1997-03-17 |
2004-07-15 |
Human Genome Sciences, Inc. |
Death domain containing receptor 5
|
CN1624128A
(zh)
*
|
1997-03-17 |
2005-06-08 |
人类基因组科学公司 |
包含死亡结构域的受体-5
|
US6872568B1
(en)
|
1997-03-17 |
2005-03-29 |
Human Genome Sciences, Inc. |
Death domain containing receptor 5 antibodies
|
US20080248046A1
(en)
*
|
1997-03-17 |
2008-10-09 |
Human Genome Sciences, Inc. |
Death domain containing receptor 5
|
US5900402A
(en)
*
|
1997-05-29 |
1999-05-04 |
Enzon, Inc. |
Method of reducing side effects associated with administration of oxygen-carrying proteins
|
US6284246B1
(en)
|
1997-07-30 |
2001-09-04 |
The Procter & Gamble Co. |
Modified polypeptides with high activity and reduced allergenicity
|
CN1276730A
(zh)
*
|
1997-09-18 |
2000-12-13 |
霍夫曼-拉罗奇有限公司 |
α-干扰素和金刚胺用于治疗慢性丙型肝炎的应用
|
ZA9811379B
(en)
*
|
1997-12-12 |
1999-08-27 |
Macromed Inc |
Hetero-functionalized star-shaped poly(ethylene glycols) for protein modification.
|
US6180095B1
(en)
|
1997-12-17 |
2001-01-30 |
Enzon, Inc. |
Polymeric prodrugs of amino- and hydroxyl-containing bioactive agents
|
WO1999030727A1
(en)
|
1997-12-17 |
1999-06-24 |
Enzon, Inc. |
Polymeric prodrugs of amino- and hydroxyl-containing bioactive agents
|
US5965119A
(en)
*
|
1997-12-30 |
1999-10-12 |
Enzon, Inc. |
Trialkyl-lock-facilitated polymeric prodrugs of amino-containing bioactive agents
|
US6624142B2
(en)
|
1997-12-30 |
2003-09-23 |
Enzon, Inc. |
Trimethyl lock based tetrapartate prodrugs
|
US7005504B2
(en)
*
|
1998-01-22 |
2006-02-28 |
Genentech, Inc. |
Antibody fragment-peg conjugates
|
US6458355B1
(en)
|
1998-01-22 |
2002-10-01 |
Genentech, Inc. |
Methods of treating inflammatory disease with anti-IL-8 antibody fragment-polymer conjugates
|
US6468532B1
(en)
|
1998-01-22 |
2002-10-22 |
Genentech, Inc. |
Methods of treating inflammatory diseases with anti-IL-8 antibody fragment-polymer conjugates
|
US6066673A
(en)
*
|
1998-03-12 |
2000-05-23 |
The Procter & Gamble Company |
Enzyme inhibitors
|
US6312685B1
(en)
|
1998-03-13 |
2001-11-06 |
Timothy C. Fisher |
Red blood cells covalently bound with two different polyethylene glycol derivatives
|
US6942859B2
(en)
|
1998-03-13 |
2005-09-13 |
University Of Southern California |
Red blood cells covalently bound with polymers
|
US6251382B1
(en)
|
1998-04-17 |
2001-06-26 |
Enzon, Inc. |
Biodegradable high molecular weight polymeric linkers and their conjugates
|
US6153655A
(en)
*
|
1998-04-17 |
2000-11-28 |
Enzon, Inc. |
Terminally-branched polymeric linkers and polymeric conjugates containing the same
|
TR200003635T2
(tr)
*
|
1998-06-08 |
2001-04-20 |
F.Hoffmann-La Roche Ag |
Peg-IFN-ALFA ve ribavirinin kronik hepatit C tedavisinde kullanılması.
|
US6214330B1
(en)
|
1998-07-13 |
2001-04-10 |
Enzon, Inc. |
Coumarin and related aromatic-based polymeric prodrugs
|
US20060188971A1
(en)
*
|
1998-08-06 |
2006-08-24 |
Duke University |
Urate oxidase
|
PT1100880E
(pt)
|
1998-08-06 |
2011-01-13 |
Univ Duke |
Urato-oxidase
|
US6783965B1
(en)
|
2000-02-10 |
2004-08-31 |
Mountain View Pharmaceuticals, Inc. |
Aggregate-free urate oxidase for preparation of non-immunogenic polymer conjugates
|
EP2158923B1
(de)
|
1998-08-06 |
2013-02-27 |
Mountain View Pharmaceuticals, Inc. |
Peg-uricase Konjugate und Verwendung davon
|
PL200586B1
(pl)
*
|
1998-10-16 |
2009-01-30 |
Biogen Idec Inc |
Polipeptydy zawierające mutanty interferonu-beta-1a, kodujące je cząsteczki kwasów nukleinowych, komórki gospodarza transformowane tymi cząsteczkami, sposób wytwarzania polipeptydów, zawierające je kompozycje farmaceutyczne i zastosowania polipeptydów
|
AU762616B2
(en)
|
1998-10-16 |
2003-07-03 |
Biogen Ma Inc. |
Polymer conjugates of interferon beta-1a and uses
|
US6458953B1
(en)
*
|
1998-12-09 |
2002-10-01 |
La Jolla Pharmaceutical Company |
Valency platform molecules comprising carbamate linkages
|
US6191290B1
(en)
*
|
1999-02-24 |
2001-02-20 |
Uab Research Foundation |
Taxane derivatives for targeted therapy of cancer
|
WO2000050620A2
(en)
|
1999-02-26 |
2000-08-31 |
Human Genome Sciences, Inc. |
Human endokine alpha and methods of use
|
US6852696B2
(en)
|
1999-03-26 |
2005-02-08 |
The University Of Texas System |
Inhibitors of glycosaminoglycans
|
US7169889B1
(en)
|
1999-06-19 |
2007-01-30 |
Biocon Limited |
Insulin prodrugs hydrolyzable in vivo to yield peglylated insulin
|
CZ299516B6
(cs)
*
|
1999-07-02 |
2008-08-20 |
F. Hoffmann-La Roche Ag |
Konjugát erythropoetinového glykoproteinu, zpusobjeho výroby a použití a farmaceutická kompozice sjeho obsahem
|
PE20010288A1
(es)
|
1999-07-02 |
2001-03-07 |
Hoffmann La Roche |
Derivados de eritropoyetina
|
DK2093245T3
(da)
|
1999-08-27 |
2012-06-04 |
Angiodevice Internat Gmbh |
Biocompatible polymer device
|
CN1111166C
(zh)
*
|
1999-09-10 |
2003-06-11 |
云南汉德生物技术有限公司 |
水溶性三尖杉磷碱聚氨基酸酯或其盐,含它们的药物组合物及其医药用途
|
US6713454B1
(en)
|
1999-09-13 |
2004-03-30 |
Nobex Corporation |
Prodrugs of etoposide and etoposide analogs
|
US6376470B1
(en)
|
1999-09-23 |
2002-04-23 |
Enzon, Inc. |
Polymer conjugates of ara-C and ara-C derivatives
|
EP2266607A3
(de)
|
1999-10-01 |
2011-04-20 |
Immunogen, Inc. |
Immunokonjugate für Krebsbehandlung
|
CA2395254C
(en)
|
1999-12-24 |
2010-05-11 |
Kyowa Hakko Kogyo Co., Ltd. |
Branched polyalkylene glycols
|
CN1188172C
(zh)
|
2000-01-10 |
2005-02-09 |
马克西根控股公司 |
G-csf偶联物
|
RU2278123C2
(ru)
|
2000-02-11 |
2006-06-20 |
Максиджен Холдингз Лтд. |
Молекулы, подобные фактору vii или viia
|
US6756037B2
(en)
|
2000-03-31 |
2004-06-29 |
Enzon, Inc. |
Polymer conjugates of biologically active agents and extension moieties for facilitating conjugation of biologically active agents to polymeric terminal groups
|
US6777387B2
(en)
|
2000-03-31 |
2004-08-17 |
Enzon Pharmaceuticals, Inc. |
Terminally-branched polymeric linkers containing extension moieties and polymeric conjugates containing the same
|
AU5019901A
(en)
*
|
2000-04-04 |
2001-10-15 |
Bioartificial Gel Technologies Inc. |
Process for the preparation of protein-based hydrogels
|
CA2405709A1
(en)
|
2000-04-12 |
2001-10-25 |
Human Genome Sciences, Inc. |
Albumin fusion proteins
|
WO2001087329A1
(en)
|
2000-05-15 |
2001-11-22 |
F. Hoffmann-La Roche Ag |
Liquid pharmaceutical composition containing an erythropoietin derivate
|
SG98393A1
(en)
|
2000-05-19 |
2003-09-19 |
Inst Materials Research & Eng |
Injectable drug delivery systems with cyclodextrin-polymer based hydrogels
|
US7259146B2
(en)
|
2000-05-26 |
2007-08-21 |
Ortho-Mcneil Pharmaceutical, Inc. |
Neuroprotective peptides
|
CN1434726A
(zh)
|
2000-06-08 |
2003-08-06 |
拉卓拉药物公司 |
包含高分子量聚环氧乙烷的多价平台分子
|
WO2001096528A2
(en)
|
2000-06-15 |
2001-12-20 |
Human Genome Sciences, Inc. |
Human tumor necrosis factor delta and epsilon
|
NZ522700A
(en)
*
|
2000-06-16 |
2006-02-24 |
Human Genome Sciences Inc |
Antibodies that immunospecifically bind to blys
|
US7879328B2
(en)
|
2000-06-16 |
2011-02-01 |
Human Genome Sciences, Inc. |
Antibodies that immunospecifically bind to B lymphocyte stimulator
|
BR0112428A
(pt)
*
|
2000-07-12 |
2003-11-25 |
Gryphon Therapeutics Inc |
Quimiocinas sintéticas boativas modificadas por polìmero e métodos para sua produção e uso
|
KR100396983B1
(ko)
*
|
2000-07-29 |
2003-09-02 |
이강춘 |
고반응성의 가지 달린 고분자 유도체 및 고분자와 단백질또는 펩타이드의 접합체
|
WO2002016411A2
(en)
*
|
2000-08-18 |
2002-02-28 |
Human Genome Sciences, Inc. |
Binding polypeptides and methods based thereon
|
DE60140773D1
(de)
|
2000-08-18 |
2010-01-21 |
Dyax Corp |
Polypeptide zur Bindung an das B-Lymphozyten-stimulatorische Protein (BLyS)
|
AU2001273385B2
(en)
*
|
2000-09-08 |
2005-04-07 |
Gryphon Therapeutics, Inc. |
Polymer-modified synthetic proteins
|
US7118737B2
(en)
*
|
2000-09-08 |
2006-10-10 |
Amylin Pharmaceuticals, Inc. |
Polymer-modified synthetic proteins
|
ES2367891T3
(es)
|
2000-09-29 |
2011-11-10 |
Schering Corporation |
Interleucina-10 pegilada.
|
US20020065397A1
(en)
|
2000-10-12 |
2002-05-30 |
Joseph Roberts |
Protecting therapeutic compositions from host-mediated inactivation
|
DE60137525D1
(de)
|
2000-10-16 |
2009-03-12 |
Chugai Pharmaceutical Co Ltd |
Peg-modifiziertes erythropoietin
|
US20030228309A1
(en)
*
|
2000-11-08 |
2003-12-11 |
Theodora Salcedo |
Antibodies that immunospecifically bind to TRAIL receptors
|
US20060062786A1
(en)
*
|
2000-11-08 |
2006-03-23 |
Human Genome Sciences, Inc. |
Antibodies that immunospecifically bind to TRAIL receptors
|
US7053150B2
(en)
|
2000-12-18 |
2006-05-30 |
Nektar Therapeutics Al, Corporation |
Segmented polymers and their conjugates
|
KR20030005204A
(ko)
*
|
2000-12-25 |
2003-01-17 |
가부시키가이샤 시세이도 |
교감신경 활성화 향료 조성물
|
ATE471956T1
(de)
*
|
2001-01-30 |
2010-07-15 |
Kyowa Hakko Kirin Co Ltd |
Verzweigte polyalkylenglykole
|
ES2284858T3
(es)
*
|
2001-02-02 |
2007-11-16 |
Ortho-Mcneil Pharmaceutical, Inc. |
Tratamiento de disfuncion neurologica que comprende sulfamatos de fructopiranosa y eritropoyetina.
|
MXPA03007392A
(es)
*
|
2001-02-20 |
2003-12-04 |
Enzon Inc |
Enlazantes polimericos ramificados terminalmente y conjugados polimericos que contienen los mismos.
|
MXPA03007619A
(es)
|
2001-02-27 |
2003-12-04 |
Maxygen Aps |
Nuevas moleculas similares a interferon beta.
|
WO2002076173A2
(en)
*
|
2001-03-21 |
2002-10-03 |
The University Of Texas System |
Inhibitors of glycosaminoglycans
|
US7348003B2
(en)
|
2001-05-25 |
2008-03-25 |
Human Genome Sciences, Inc. |
Methods of treating cancer using antibodies that immunospecifically bind to TRAIL receptors
|
NZ529359A
(en)
|
2001-05-25 |
2007-04-27 |
Human Genome Sciences Inc |
Antibodies that immunospecifically bind to a TR4 polypeptide or polypeptide fragment or variant of TR4 and their use in a medicament for treating cancer
|
US20050214209A1
(en)
*
|
2001-05-25 |
2005-09-29 |
Human Genome Sciences, Inc. |
Antibodies that immunospecifically bind to TRAIL receptors
|
US7361341B2
(en)
*
|
2001-05-25 |
2008-04-22 |
Human Genome Sciences, Inc. |
Methods of treating cancer using antibodies that immunospecifically bind to trail receptors
|
US20090226429A1
(en)
*
|
2001-05-25 |
2009-09-10 |
Human Genome Sciences, Inc. |
Antibodies That Immunospecifically Bind to TRAIL Receptors
|
US6858580B2
(en)
|
2001-06-04 |
2005-02-22 |
Nobex Corporation |
Mixtures of drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
|
US6835802B2
(en)
|
2001-06-04 |
2004-12-28 |
Nobex Corporation |
Methods of synthesizing substantially monodispersed mixtures of polymers having polyethylene glycol moieties
|
US6713452B2
(en)
|
2001-06-04 |
2004-03-30 |
Nobex Corporation |
Mixtures of calcitonin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
|
US7713932B2
(en)
|
2001-06-04 |
2010-05-11 |
Biocon Limited |
Calcitonin drug-oligomer conjugates, and uses thereof
|
US6828305B2
(en)
*
|
2001-06-04 |
2004-12-07 |
Nobex Corporation |
Mixtures of growth hormone drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
|
US6828297B2
(en)
|
2001-06-04 |
2004-12-07 |
Nobex Corporation |
Mixtures of insulin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
|
US20040077835A1
(en)
*
|
2001-07-12 |
2004-04-22 |
Robin Offord |
Chemokine receptor modulators, production and use
|
DE60223047T2
(de)
*
|
2001-08-22 |
2008-07-24 |
Bioartificial Gel Technologies Inc., Montreal |
Verfahren zur herstellung von aktivierten polyethylenglykolen
|
GB0121709D0
(en)
*
|
2001-09-07 |
2001-10-31 |
Imp College Innovations Ltd |
Food inhibition agent
|
DE60230818D1
(de)
*
|
2001-09-24 |
2009-02-26 |
Imp Innovations Ltd |
Pyy3-36 zur zur reduzierung oder vorbeugung von fettleibigkeit
|
US7157277B2
(en)
|
2001-11-28 |
2007-01-02 |
Neose Technologies, Inc. |
Factor VIII remodeling and glycoconjugation of Factor VIII
|
US7214660B2
(en)
|
2001-10-10 |
2007-05-08 |
Neose Technologies, Inc. |
Erythropoietin: remodeling and glycoconjugation of erythropoietin
|
US7173003B2
(en)
|
2001-10-10 |
2007-02-06 |
Neose Technologies, Inc. |
Granulocyte colony stimulating factor: remodeling and glycoconjugation of G-CSF
|
US8008252B2
(en)
|
2001-10-10 |
2011-08-30 |
Novo Nordisk A/S |
Factor VII: remodeling and glycoconjugation of Factor VII
|
US7795210B2
(en)
|
2001-10-10 |
2010-09-14 |
Novo Nordisk A/S |
Protein remodeling methods and proteins/peptides produced by the methods
|
KR100948532B1
(ko)
*
|
2001-11-07 |
2010-03-23 |
넥타르 테라퓨틱스 |
분지형 중합체 및 그의 공액체
|
US6818613B2
(en)
|
2001-11-07 |
2004-11-16 |
Ortho-Mcneil Pharmaceutical, Inc. |
Aqueous sustained-release formulations of proteins
|
US20030171285A1
(en)
*
|
2001-11-20 |
2003-09-11 |
Finn Rory F. |
Chemically-modified human growth hormone conjugates
|
US7232797B2
(en)
*
|
2001-11-28 |
2007-06-19 |
Ortho-Mcneil Pharmaceutical, Inc. |
Erythropoietin dosing regimen for treating anemia
|
NZ532881A
(en)
*
|
2001-12-20 |
2008-04-30 |
Human Genome Sciences Inc |
Antibodies that immunospecifically bind to trail receptors
|
CA2471363C
(en)
|
2001-12-21 |
2014-02-11 |
Human Genome Sciences, Inc. |
Albumin fusion proteins
|
EP1474163A2
(de)
|
2002-01-10 |
2004-11-10 |
Imperial College Innovations Limited |
Veränderung des fütterungsverhaltens
|
US8058233B2
(en)
*
|
2002-01-10 |
2011-11-15 |
Oregon Health And Science University |
Modification of feeding behavior using PYY and GLP-1
|
US7144978B2
(en)
|
2002-01-15 |
2006-12-05 |
Pan Asia Bio Co., Ltd. |
Multidrop tree branching functional polyethylene glycol, methods of preparing and using same
|
US7129267B2
(en)
*
|
2002-03-11 |
2006-10-31 |
Janssen Pharmaceutica N.V. |
Methods for SHP1 mediated neuroprotection
|
US8003089B2
(en)
*
|
2002-03-13 |
2011-08-23 |
Beijing Jiankai Technology Co., Ltd. |
Y shape branched hydrophilic polymer derivatives, their preparation methods, conjugates of the derivatives and drug molecules, and pharmaceutical compositions comprising the conjugates
|
US7557195B2
(en)
*
|
2002-03-20 |
2009-07-07 |
Biopolymed, Inc. |
Stoichiometric conjugates of biocompatible polymers at the unpaired cysteine residue of the wild-type G-CSF
|
AU2003218456A1
(en)
*
|
2002-04-01 |
2003-10-20 |
Human Genome Sciences, Inc. |
Antibodies that specifically bind to gmad
|
ITMI20020951A1
(it)
*
|
2002-05-06 |
2003-11-06 |
Univ Degli Studi Trieste |
Derivati multifunzionali del polietilenglicole loro preparazione ed impiego
|
EP1534753B1
(de)
*
|
2002-05-28 |
2011-08-03 |
UCB Pharma, S.A. |
Peg-positionsisomer von einem antikorper gegen tnfalpha (cdp870)
|
AU2003240439B2
(en)
|
2002-06-21 |
2009-05-21 |
Novo Nordisk Health Care Ag |
Pegylated factor VII glycoforms
|
MXPA04012496A
(es)
|
2002-06-21 |
2005-09-12 |
Novo Nordisk Healthcare Ag |
Glicoformos del factor vii pegilados.
|
CN1671400A
(zh)
*
|
2002-07-03 |
2005-09-21 |
派瑞克科学公司 |
透明质酸组合物以及使用方法
|
CA2490007C
(en)
|
2002-07-19 |
2011-05-24 |
Omeros Corporation |
Biodegradable triblock copolymers, synthesis methods therefor, and hydrogels and biomaterials made there from
|
US7122189B2
(en)
*
|
2002-08-13 |
2006-10-17 |
Enzon, Inc. |
Releasable polymeric conjugates based on aliphatic biodegradable linkers
|
US7413738B2
(en)
|
2002-08-13 |
2008-08-19 |
Enzon Pharmaceuticals, Inc. |
Releasable polymeric conjugates based on biodegradable linkers
|
US7087229B2
(en)
*
|
2003-05-30 |
2006-08-08 |
Enzon Pharmaceuticals, Inc. |
Releasable polymeric conjugates based on aliphatic biodegradable linkers
|
WO2004019861A2
(en)
*
|
2002-08-28 |
2004-03-11 |
Pharmacia Corporation |
Stable ph optimized formulation of a modified antibody
|
US20040247588A1
(en)
*
|
2002-08-28 |
2004-12-09 |
Johnson Robert E. |
Formulations of modified antibodies and methods of making the same
|
US7459435B2
(en)
|
2002-08-29 |
2008-12-02 |
Hoffmann-La Roche Inc. |
Treatment of disturbances of iron distribution
|
US8129330B2
(en)
*
|
2002-09-30 |
2012-03-06 |
Mountain View Pharmaceuticals, Inc. |
Polymer conjugates with decreased antigenicity, methods of preparation and uses thereof
|
US20040062748A1
(en)
|
2002-09-30 |
2004-04-01 |
Mountain View Pharmaceuticals, Inc. |
Polymer conjugates with decreased antigenicity, methods of preparation and uses thereof
|
TWI281864B
(en)
*
|
2002-11-20 |
2007-06-01 |
Pharmacia Corp |
N-terminally monopegylated human growth hormone conjugates and process for their preparation
|
US7459436B2
(en)
|
2002-11-22 |
2008-12-02 |
Hoffmann-La Roche Inc. |
Treatment of disturbances of iron distribution
|
RS20050501A
(en)
*
|
2002-12-26 |
2007-08-03 |
Mountain View Pharmaceuticals Inc., |
Polymer conjugates of cytokines,chemokines,growth factors, polypeptide hormones and antagonists thereof with preserved receptor-binding activity
|
WO2004060299A2
(en)
*
|
2002-12-26 |
2004-07-22 |
Mountain View Pharmaceuticals, Inc. |
Polymer conjugates of interferon-beta with enhanced biological potency
|
WO2004061094A1
(en)
|
2002-12-30 |
2004-07-22 |
Gryphon Therapeutics, Inc. |
Water-soluble thioester and selenoester compounds and methods for making and using the same
|
CA2511486A1
(en)
*
|
2002-12-30 |
2004-07-22 |
Angiotech International Ag |
Tissue reactive compounds and compositions and uses thereof
|
US20040225077A1
(en)
*
|
2002-12-30 |
2004-11-11 |
Angiotech International Ag |
Drug delivery from rapid gelling polymer composition
|
GB0300571D0
(en)
*
|
2003-01-10 |
2003-02-12 |
Imp College Innovations Ltd |
Modification of feeding behaviour
|
US20090123367A1
(en)
*
|
2003-03-05 |
2009-05-14 |
Delfmems |
Soluble Glycosaminoglycanases and Methods of Preparing and Using Soluble Glycosaminoglycanases
|
CA2517145C
(en)
*
|
2003-03-05 |
2017-08-01 |
Halozyme, Inc. |
Soluble hyaluronidase glycoprotein (shasegp), process for preparing the same, uses and pharmaceutical compositions comprising thereof
|
US20060104968A1
(en)
|
2003-03-05 |
2006-05-18 |
Halozyme, Inc. |
Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
|
US7871607B2
(en)
*
|
2003-03-05 |
2011-01-18 |
Halozyme, Inc. |
Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
|
CA2519092C
(en)
|
2003-03-14 |
2014-08-05 |
Neose Technologies, Inc. |
Branched water-soluble polymers and their conjugates
|
US8791070B2
(en)
|
2003-04-09 |
2014-07-29 |
Novo Nordisk A/S |
Glycopegylated factor IX
|
PL1615945T3
(pl)
|
2003-04-09 |
2012-03-30 |
Ratiopharm Gmbh |
Sposoby glikopegylacji i białka/peptydy wytwarzane tymi sposobami
|
WO2004091517A2
(en)
|
2003-04-15 |
2004-10-28 |
Smithkline Beecham Corporation |
Conjugates comprising human il-18 and substitution mutants thereof
|
BRPI0410164A
(pt)
*
|
2003-05-09 |
2006-05-16 |
Neose Technologies Inc |
composições e métodos para preparação de mutantes de glicosilação de hormÈnio do crescimento humano
|
US20070172446A1
(en)
|
2003-05-16 |
2007-07-26 |
Intermune, Inc. |
Synthetic chemokine receptor ligands and methods of use thereof
|
TR201907313T4
(tr)
*
|
2003-05-23 |
2019-06-21 |
Nektar Therapeutics |
İki PEG zinciri içeren PEG türevleri.
|
US7947261B2
(en)
|
2003-05-23 |
2011-05-24 |
Nektar Therapeutics |
Conjugates formed from polymer derivatives having particular atom arrangements
|
US9005625B2
(en)
|
2003-07-25 |
2015-04-14 |
Novo Nordisk A/S |
Antibody toxin conjugates
|
WO2005023294A2
(en)
|
2003-09-05 |
2005-03-17 |
The General Hospital Corporation |
Polyacetal drug conjugates as release system
|
EP1525890A1
(de)
*
|
2003-10-02 |
2005-04-27 |
Complex Biosystems GmbH |
Protein-Proteophor Komplex
|
WO2005035727A2
(en)
*
|
2003-10-09 |
2005-04-21 |
Ambrx, Inc. |
Polymer derivatives
|
ATE481420T1
(de)
|
2003-10-10 |
2010-10-15 |
Novo Nordisk As |
Il-21-derivate
|
DK1680137T3
(da)
|
2003-10-14 |
2013-02-18 |
Hoffmann La Roche |
Makrocyklisk carboxylsyre- og acylsulfonamidforbindelse som inhibitor af HCV-replikation
|
ES2428358T3
(es)
|
2003-10-17 |
2013-11-07 |
Novo Nordisk A/S |
Terapia de combinación
|
US7407973B2
(en)
*
|
2003-10-24 |
2008-08-05 |
Intermune, Inc. |
Use of pirfenidone in therapeutic regimens
|
US20080305992A1
(en)
|
2003-11-24 |
2008-12-11 |
Neose Technologies, Inc. |
Glycopegylated erythropoietin
|
US8633157B2
(en)
|
2003-11-24 |
2014-01-21 |
Novo Nordisk A/S |
Glycopegylated erythropoietin
|
KR20060120141A
(ko)
*
|
2003-11-24 |
2006-11-24 |
네오스 테크놀로지스, 인크. |
글리코페질화 에리트로포이에틴
|
US7956032B2
(en)
|
2003-12-03 |
2011-06-07 |
Novo Nordisk A/S |
Glycopegylated granulocyte colony stimulating factor
|
WO2005056760A2
(en)
*
|
2003-12-03 |
2005-06-23 |
Neose Technologies, Inc. |
Glycopegylated follicle stimulating hormone
|
US20060040856A1
(en)
*
|
2003-12-03 |
2006-02-23 |
Neose Technologies, Inc. |
Glycopegylated factor IX
|
CN102895666B
(zh)
*
|
2003-12-16 |
2015-08-19 |
尼克塔治疗公司 |
化学改性的小分子
|
US20060182692A1
(en)
*
|
2003-12-16 |
2006-08-17 |
Fishburn C S |
Chemically modified small molecules
|
SI1696947T1
(sl)
|
2003-12-19 |
2014-05-30 |
F. Hoffmann-La Roche Ag |
Uporaba eritropoetina pri zdravljenju motenj porazdelitve železa pri kroničnih vnetnih črevesnih boleznih
|
KR101439880B1
(ko)
|
2004-01-08 |
2014-09-12 |
라티오팜 게엠베하 |
펩티드의 오-결합형 글리코실화
|
AU2005211385B2
(en)
|
2004-02-02 |
2008-12-11 |
Ambrx, Inc. |
Modified human growth hormone polypeptides and their uses
|
MXPA06009072A
(es)
|
2004-02-09 |
2007-03-29 |
Human Genome Sciences Inc |
Proteinas de fusion de albumina.
|
US6887952B1
(en)
|
2004-02-12 |
2005-05-03 |
Biosite, Inc. |
N-aryl-carbamic acid ester-derived and valeric acid ester-derived cross-linkers and conjugates, and methods for their synthesis and use
|
US7351787B2
(en)
|
2004-03-05 |
2008-04-01 |
Bioartificial Gel Technologies, Inc. |
Process for the preparation of activated polyethylene glycols
|
US20050238628A1
(en)
*
|
2004-04-08 |
2005-10-27 |
Blau Carl A |
Methods for treating cancer
|
WO2006083260A2
(en)
|
2004-04-28 |
2006-08-10 |
Angiotech Biomaterials Corporation |
Compositions and systems for forming crosslinked biomaterials and associated methods of preparation and use
|
US8562965B2
(en)
|
2004-05-03 |
2013-10-22 |
Nektar Therapeutics |
Polymer derivatives comprising an acetal or ketal branching point
|
WO2006009901A2
(en)
*
|
2004-06-18 |
2006-01-26 |
Ambrx, Inc. |
Novel antigen-binding polypeptides and their uses
|
EP1771066A2
(de)
|
2004-07-13 |
2007-04-11 |
Neose Technologies, Inc. |
Remodellierung von verzweigtem peg und klykolysierung von glucagonähnlichem peptide-1 glp-1
|
CA2580313C
(en)
|
2004-07-19 |
2016-03-15 |
Biocon Limited |
Insulin-oligomer conjugates, formulations and uses thereof
|
US7638299B2
(en)
*
|
2004-07-21 |
2009-12-29 |
Ambrx, Inc. |
Biosynthetic polypeptides utilizing non-naturally encoded amino acids
|
US20090292110A1
(en)
*
|
2004-07-23 |
2009-11-26 |
Defrees Shawn |
Enzymatic modification of glycopeptides
|
US7772182B2
(en)
*
|
2004-08-05 |
2010-08-10 |
Alza Corporation |
Stable suspension formulations of erythropoietin receptor agonists
|
EP1789074A4
(de)
*
|
2004-08-09 |
2009-08-12 |
Alios Biopharma Inc |
Synthetische hyperglycosylierte, protease-resistente polypeptid-varianten, orale formulierungen und anwendungsverfahren dafür
|
US7597884B2
(en)
|
2004-08-09 |
2009-10-06 |
Alios Biopharma, Inc. |
Hyperglycosylated polypeptide variants and methods of use
|
US20060051825A1
(en)
*
|
2004-09-09 |
2006-03-09 |
Buechler Kenneth F |
Methods and compositions for measuring canine BNP and uses thereof
|
EP1799249A2
(de)
|
2004-09-10 |
2007-06-27 |
Neose Technologies, Inc. |
Glycopegyliertes interferon alpha
|
WO2006034128A2
(en)
|
2004-09-17 |
2006-03-30 |
Angiotech Biomaterials Corporation |
Multifunctional compounds for forming crosslinked biomaterials and methods of preparation and use
|
EP1796746B1
(de)
|
2004-10-07 |
2011-05-04 |
E.I. Du Pont De Nemours And Company |
Polymer auf basis von polysaccharide für gewebekleber zur medizinischen verwendung
|
US8790632B2
(en)
*
|
2004-10-07 |
2014-07-29 |
Actamax Surgical Materials, Llc |
Polymer-based tissue-adhesive form medical use
|
WO2006050247A2
(en)
|
2004-10-29 |
2006-05-11 |
Neose Technologies, Inc. |
Remodeling and glycopegylation of fibroblast growth factor (fgf)
|
MX2007007591A
(es)
*
|
2004-12-22 |
2007-07-25 |
Ambrx Inc |
Metodos para expresion y purificacion de hormona de crecimiento humano recombinante.
|
MX2007007590A
(es)
|
2004-12-22 |
2007-12-10 |
Ambrx Inc |
Composiciones que contienen, metodos que involucran y usos de aminoacidos no naturales y polipeptidos.
|
EP1836298B1
(de)
*
|
2004-12-22 |
2012-01-18 |
Ambrx, Inc. |
Zusammensetzungen von aminoacyl-trna-synthetase und verwendungen davon
|
US7816320B2
(en)
|
2004-12-22 |
2010-10-19 |
Ambrx, Inc. |
Formulations of human growth hormone comprising a non-naturally encoded amino acid at position 35
|
ATE542920T1
(de)
*
|
2004-12-22 |
2012-02-15 |
Ambrx Inc |
Modifiziertes menschliches wachstumshormon
|
NZ556436A
(en)
|
2005-01-10 |
2010-11-26 |
Biogenerix Ag |
Glycopegylated granulocyte colony stimulating factor
|
WO2006078813A2
(en)
*
|
2005-01-21 |
2006-07-27 |
Biosite Incorporated |
Arginine analogs, and methods for their synthesis and use
|
US7365127B2
(en)
|
2005-02-04 |
2008-04-29 |
Enzon Pharmaceuticals, Inc. |
Process for the preparation of polymer conjugates
|
WO2006086617A2
(en)
*
|
2005-02-10 |
2006-08-17 |
Emory University |
Polyethylene oxide polymers including anti-inflammatory glycodendrons
|
CN101238142B
(zh)
*
|
2005-02-18 |
2012-11-14 |
国立大学法人德岛大学 |
含聚氧化烯链的脂质衍生物及含有该衍生物的脂质膜结构体
|
JP4877225B2
(ja)
|
2005-02-18 |
2012-02-15 |
日油株式会社 |
ポリオキシアルキレン誘導体
|
WO2006105993A2
(en)
|
2005-04-05 |
2006-10-12 |
Istituto Di Ricerche Di Biologia Molecolare P Angeletti Spa |
Method for shielding functional sites or epitopes on proteins
|
EP2386571B1
(de)
|
2005-04-08 |
2016-06-01 |
ratiopharm GmbH |
Zusammensetzungen und Verfahren zur Herstellung von Glycosylierungsmutanten eines Proteaseresistenten menschlichen Wachstumshormons
|
PL3321359T3
(pl)
|
2005-04-11 |
2021-06-28 |
Horizon Pharma Rheumatology Llc |
Wariantowe postacie oksydazy moczanowej i ich zastosowanie
|
US20080159976A1
(en)
*
|
2005-04-11 |
2008-07-03 |
Jacob Hartman |
Methods for lowering elevated uric acid levels using intravenous injections of PEG-uricase
|
US8148123B2
(en)
*
|
2005-04-11 |
2012-04-03 |
Savient Pharmaceuticals, Inc. |
Methods for lowering elevated uric acid levels using intravenous injections of PEG-uricase
|
RU2435847C2
(ru)
|
2005-04-11 |
2011-12-10 |
Савиент Фармасьютикалз, Инк. |
Вариантная форма урат-оксидазы и ее использование
|
EP1885403B1
(de)
|
2005-04-12 |
2013-05-08 |
Nektar Therapeutics |
Poly(ethylenglykol)-Konjugate von Lysostaphin
|
US7833979B2
(en)
*
|
2005-04-22 |
2010-11-16 |
Amgen Inc. |
Toxin peptide therapeutic agents
|
WO2006125452A1
(en)
*
|
2005-05-23 |
2006-11-30 |
Universite De Geneve |
Injectable superparamagnetic nanoparticles for treatment by hyperthermia and use for forming an hyperthermic implant
|
WO2006127910A2
(en)
|
2005-05-25 |
2006-11-30 |
Neose Technologies, Inc. |
Glycopegylated erythropoietin formulations
|
JP5216580B2
(ja)
|
2005-05-25 |
2013-06-19 |
ノヴォ ノルディスク アー/エス |
グリコペグ化第ix因子
|
CN103030690A
(zh)
*
|
2005-06-03 |
2013-04-10 |
Ambrx公司 |
经改良人类干扰素分子和其用途
|
GB0511986D0
(en)
*
|
2005-06-13 |
2005-07-20 |
Imp College Innovations Ltd |
Novel compounds and their effects on feeding behaviour
|
WO2006134173A2
(en)
|
2005-06-17 |
2006-12-21 |
Novo Nordisk Health Care Ag |
Selective reduction and derivatization of engineered proteins comprising at least one non-native cysteine
|
EP2412744B1
(de)
|
2005-07-18 |
2014-01-22 |
Nektar Therapeutics |
Verfahren zur Herstellung von verzweigten funktionalisierten Polymeren mithilfe von verzweigten Polyol-Kernen
|
KR100735784B1
(ko)
*
|
2005-07-20 |
2007-07-06 |
재단법인 목암생명공학연구소 |
인간 과립구콜로니자극인자 변이체 및 이의 화학적 접합물
|
US8008453B2
(en)
|
2005-08-12 |
2011-08-30 |
Amgen Inc. |
Modified Fc molecules
|
KR101285904B1
(ko)
|
2005-08-18 |
2013-07-15 |
암브룩스, 인코포레이티드 |
tRNA 조성물 및 이의 용도
|
US20070105755A1
(en)
|
2005-10-26 |
2007-05-10 |
Neose Technologies, Inc. |
One pot desialylation and glycopegylation of therapeutic peptides
|
US8679537B2
(en)
*
|
2005-08-24 |
2014-03-25 |
Actamaz Surgical Materials, LLC |
Methods for sealing an orifice in tissue using an aldol-crosslinked polymeric hydrogel adhesive
|
US8679536B2
(en)
*
|
2005-08-24 |
2014-03-25 |
Actamax Surgical Materials, Llc |
Aldol-crosslinked polymeric hydrogel adhesives
|
US7601798B2
(en)
*
|
2005-10-04 |
2009-10-13 |
Enzon Pharmaceuticals, Inc. |
Methods of preparing polymers having terminal amine groups using protected amine salts
|
WO2007142667A2
(en)
*
|
2005-10-13 |
2007-12-13 |
Human Genome Sciences, Inc. |
Treatment of patients with autoantibody positive disease
|
US9168286B2
(en)
*
|
2005-10-13 |
2015-10-27 |
Human Genome Sciences, Inc. |
Methods and compositions for use in treatment of patients with autoantibody positive disease
|
US20090048440A1
(en)
|
2005-11-03 |
2009-02-19 |
Neose Technologies, Inc. |
Nucleotide Sugar Purification Using Membranes
|
CN101400646A
(zh)
*
|
2005-11-08 |
2009-04-01 |
Ambrx公司 |
用于修饰非天然氨基酸和非天然氨基酸多肽的促进剂
|
US20090018029A1
(en)
*
|
2005-11-16 |
2009-01-15 |
Ambrx, Inc. |
Methods and Compositions Comprising Non-Natural Amino Acids
|
CN105384807A
(zh)
*
|
2005-12-14 |
2016-03-09 |
Ambrx公司 |
含有非天然氨基酸和多肽的组合物、涉及非天然氨基酸和多肽的方法以及非天然氨基酸和多肽的用途
|
US7989554B2
(en)
|
2006-01-10 |
2011-08-02 |
Enzon Pharmaceuticals, Inc. |
Reacting polyalkylene oxide with base, tertiary alkyl haloacetate, then acid to prepare polyalkylene oxide carboxylic acid
|
US8946155B2
(en)
|
2006-02-03 |
2015-02-03 |
Opko Biologics Ltd. |
Long-acting polypeptides and methods of producing and administering same
|
US10221228B2
(en)
|
2006-02-03 |
2019-03-05 |
Opko Biologics Ltd. |
Long-acting polypeptides and methods of producing and administering same
|
US9458444B2
(en)
|
2006-02-03 |
2016-10-04 |
Opko Biologics Ltd. |
Long-acting coagulation factors and methods of producing same
|
US20140113860A1
(en)
|
2006-02-03 |
2014-04-24 |
Prolor Biotech Ltd. |
Long-acting polypeptides and methods of producing and administering same
|
US20150038413A1
(en)
|
2006-02-03 |
2015-02-05 |
Opko Biologics Ltd. |
Long-acting polypeptides and methods of producing and administering same
|
US10351615B2
(en)
|
2006-02-03 |
2019-07-16 |
Opko Biologics Ltd. |
Methods of treatment with long-acting growth hormone
|
US9249407B2
(en)
|
2006-02-03 |
2016-02-02 |
Opko Biologics Ltd. |
Long-acting coagulation factors and methods of producing same
|
US8048849B2
(en)
|
2006-02-03 |
2011-11-01 |
Modigene, Inc. |
Long-acting polypeptides and methods of producing same
|
JP5528710B2
(ja)
*
|
2006-02-28 |
2014-06-25 |
オリガシス コーポレイション |
アクリロイルオキシエチルホスホリルコリン含有ポリマー抱合体及びその製法
|
NZ571183A
(en)
|
2006-03-13 |
2010-09-30 |
Liat Mintz |
Use of ghrelin splice variant for treating cachexia and/or anorexia and/or anorexia-cachexia and/or malnutrition and/or lipodystrophy and/or muscle wasting and/or appetite stimulation
|
WO2007123765A2
(en)
|
2006-03-31 |
2007-11-01 |
Human Genome Sciences Inc. |
Neutrokine-alpha and neutrokine-alpha splice variant
|
ES2532804T3
(es)
*
|
2006-04-12 |
2015-03-31 |
Crealta Pharmaceuticals Llc |
Purificación de proteínas con tensioactivo catiónico
|
CN101062407A
(zh)
|
2006-04-29 |
2007-10-31 |
中国科学院上海生命科学研究院 |
促红细胞生成素在预防或治疗视网膜损伤中的用途
|
US20080096819A1
(en)
*
|
2006-05-02 |
2008-04-24 |
Allozyne, Inc. |
Amino acid substituted molecules
|
EP2018437A2
(de)
|
2006-05-02 |
2009-01-28 |
Allozyne, Inc. |
Mit nicht-natürlichen aminosäuren substituierte polypeptide
|
CN104593348A
(zh)
|
2006-05-24 |
2015-05-06 |
诺沃—诺迪斯克保健股份有限公司 |
具有延长的体内半寿期的因子ix类似物
|
JP2009539879A
(ja)
*
|
2006-06-09 |
2009-11-19 |
エンゾン ファーマスーティカルズ インコーポレイテッド |
インデノイソキノリン放出性ポリマー複合体
|
WO2008011234A2
(en)
*
|
2006-06-30 |
2008-01-24 |
Enzon Pharmaceuticals, Inc. |
Recombinant host for producing l-asparaginase ii
|
ES2516694T3
(es)
|
2006-07-21 |
2014-10-31 |
Ratiopharm Gmbh |
Glicosilación de péptidos a través de secuencias de glicosilación con unión en O
|
EP2054437A2
(de)
*
|
2006-08-07 |
2009-05-06 |
Teva Biopharmaceuticals USA, Inc. |
Albumin-insulin-fusionsproteine
|
JP5451390B2
(ja)
*
|
2006-09-08 |
2014-03-26 |
アンブルックス,インコーポレイテッド |
脊椎動物細胞内におけるサプレッサーtrnaの転写
|
AU2007292903B2
(en)
|
2006-09-08 |
2012-03-29 |
Ambrx, Inc. |
Modified human plasma polypeptide or Fc scaffolds and their uses
|
SG174781A1
(en)
*
|
2006-09-08 |
2011-10-28 |
Ambrx Inc |
Hybrid suppressor trna for vertebrate cells
|
US8110559B2
(en)
*
|
2006-09-15 |
2012-02-07 |
Enzon Pharmaceuticals, Inc. |
Hindered ester-based biodegradable linkers for oligonucleotide delivery
|
US8367065B2
(en)
*
|
2006-09-15 |
2013-02-05 |
Enzon Pharmaceuticals, Inc. |
Targeted polymeric prodrugs containing multifunctional linkers
|
RU2009114154A
(ru)
*
|
2006-09-15 |
2010-10-20 |
Энзон Фармасьютикалз, Инк. (Us) |
Полимерные пролекарства с направленной доставкой, содержащие полифункциональные линкеры
|
US7985783B2
(en)
|
2006-09-21 |
2011-07-26 |
The Regents Of The University Of California |
Aldehyde tags, uses thereof in site-specific protein modification
|
EP2468293B1
(de)
|
2006-09-28 |
2014-10-22 |
Merck Sharp & Dohme Corp. |
Verwendung von pegyliertem il-10 zur verhinderung von lungenkrebs metastasen
|
WO2008057683A2
(en)
*
|
2006-10-03 |
2008-05-15 |
Novo Nordisk A/S |
Methods for the purification of polypeptide conjugates
|
LT2068907T
(lt)
|
2006-10-04 |
2018-01-10 |
Novo Nordisk A/S |
Glicerolio sujungti pegilinti sacharidai ir glikopeptidai
|
WO2008051383A2
(en)
*
|
2006-10-19 |
2008-05-02 |
Amgen Inc. |
Use of alcohol co-solvents to improve pegylation reaction yields
|
CN101168594B
(zh)
*
|
2006-10-24 |
2011-07-27 |
北京键凯科技有限公司 |
寡肽为骨架的聚乙二醇活性衍生物、其制备方法及与药物分子的结合物
|
AR063384A1
(es)
*
|
2006-10-25 |
2009-01-28 |
Amgen Inc |
Agentes terapeuticos a base de peptidos derivados de toxinas
|
CN101541857B
(zh)
*
|
2006-11-27 |
2012-12-12 |
阿克塔马克斯手术器材有限责任公司 |
多官能聚环氧烷、水凝胶和组织粘合剂
|
TWI428346B
(zh)
*
|
2006-12-13 |
2014-03-01 |
Imp Innovations Ltd |
新穎化合物及其等對進食行為影響
|
JP5340956B2
(ja)
*
|
2006-12-20 |
2013-11-13 |
アーケマ・インコーポレイテッド |
ポリマーの封入および/または結合
|
US20080159964A1
(en)
*
|
2006-12-29 |
2008-07-03 |
Enzon Pharmaceuticals, Inc. |
Use of adenosine deaminase for treating pulmonary disease
|
EP2125014A2
(de)
*
|
2007-01-16 |
2009-12-02 |
Enzon Pharmaceuticals, Inc. |
Posaconazol-polymer-konjugate und behandlungsverfahren mithilfe von posaconazol und polymer-konjugaten davon
|
US20080254188A1
(en)
*
|
2007-02-01 |
2008-10-16 |
National Research Council Of Canada |
Formulations of lipophilic bioactive molecules
|
KR101476472B1
(ko)
*
|
2007-03-30 |
2015-01-05 |
암브룩스, 인코포레이티드 |
변형된 fgf-21 폴리펩티드 및 그 용도
|
BRPI0809670A8
(pt)
|
2007-04-03 |
2018-12-18 |
Biogenerix Ag |
métodos para aumentar a produção de célula tronco, para aumentar o número de granulócitos em um indivíduo, para prevenir, tratar e aliviar a mielossupressão que resulta de uma terapia contra o câncer, para tratar uma condição em um indivíduo, para tratar neutropenia e trombocitopenia em um mamífero, para expandir células tronco hematopoiéticas em cultura, para aumentar a hematopoiese em um indivíduo, para aumentar o número de célulars progenitoras hematopoiéticas em um indivíduo, e para fornecer enxerto estável da medula óssea, e, forma de dosagem oral.
|
HUE027603T2
(en)
*
|
2007-04-20 |
2016-10-28 |
Sigma-Tau Rare Disease Ltd |
Stable, recombinant adenosine deaminase
|
EP2147122B1
(de)
*
|
2007-04-20 |
2014-07-16 |
Sigma-Tau Rare Diseases S.A. |
Enzymatische tumortherapie
|
CA2685596A1
(en)
|
2007-05-02 |
2008-11-13 |
Ambrx, Inc. |
Modified interferon beta polypeptides and their uses
|
AU2008262490B2
(en)
*
|
2007-05-22 |
2011-11-17 |
Amgen Inc. |
Compositions and methods for producing bioactive fusion proteins
|
CN101778859B
(zh)
|
2007-06-12 |
2014-03-26 |
诺和诺德公司 |
改良的用于生产核苷酸糖的方法
|
TW200922624A
(en)
*
|
2007-07-11 |
2009-06-01 |
Enzon Pharmaceuticals Inc |
Polymeric drug delivery system containing a multi-substituted aromatic moiety
|
CL2008002399A1
(es)
*
|
2007-08-16 |
2009-01-02 |
Pharmaessentia Corp |
Conjugado sustancialmente puro que posee una porcion polimerica, una porcion proteica (interferon alfa 2b) y un ligante alifatico de 1 a 10 atomos de carbono, util en el tratamiento de las hepatitis b o c.
|
CA2707840A1
(en)
|
2007-08-20 |
2009-02-26 |
Allozyne, Inc. |
Amino acid substituted molecules
|
US8207112B2
(en)
|
2007-08-29 |
2012-06-26 |
Biogenerix Ag |
Liquid formulation of G-CSF conjugate
|
US8088884B2
(en)
*
|
2007-09-27 |
2012-01-03 |
Serina Therapeutics, Inc. |
Multi-armed forms of activated polyoxazoline and methods of synthesis thereof
|
BRPI0818004B8
(pt)
|
2007-10-16 |
2021-05-25 |
Biocon Ltd |
composição farmacêutica sólida administrável por via oral e o processo da mesma.
|
WO2009064977A2
(en)
|
2007-11-14 |
2009-05-22 |
E.I. Du Pont De Nemours And Company |
Dextran-based polymer tissue adhesive for medical use
|
EP2214731B1
(de)
*
|
2007-11-14 |
2014-05-14 |
Actamax Surgical Materials LLC |
Auf oxidiertem kationischem polysaccharid basierendes polymergewebehaftmittel zur medizinischen verwendung
|
NZ584825A
(en)
|
2007-11-20 |
2013-03-28 |
Ambrx Inc |
Modified insulin polypeptides and their uses
|
JP5514736B2
(ja)
|
2008-01-11 |
2014-06-04 |
セリナ・セラピユーテイツクス・インコーポレーテツド |
ポリオキサゾリン共重合体の多機能形態およびそれを含む薬物組成物
|
US8101706B2
(en)
*
|
2008-01-11 |
2012-01-24 |
Serina Therapeutics, Inc. |
Multifunctional forms of polyoxazoline copolymers and drug compositions comprising the same
|
JP5702150B2
(ja)
|
2008-02-08 |
2015-04-15 |
アンブルックス, インコーポレイテッドAmbrx, Inc. |
修飾されているレプチンポリペプチドおよびそれらの使用
|
CN103497246B
(zh)
|
2008-02-27 |
2016-08-10 |
诺沃—诺迪斯克有限公司 |
缀合的因子viii分子
|
TWI395593B
(zh)
|
2008-03-06 |
2013-05-11 |
Halozyme Inc |
可活化的基質降解酵素之活體內暫時性控制
|
EP2260102A1
(de)
|
2008-03-25 |
2010-12-15 |
Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research |
Tumorbehandlung mittels herunterregelung von frizzled-4 und/oder frizzled-1
|
AU2009236635B2
(en)
|
2008-04-14 |
2014-02-13 |
Halozyme, Inc. |
Modified hyaluronidases and uses in treating hyaluronan-associated diseases and conditions
|
CA2720048A1
(en)
|
2008-04-16 |
2009-10-22 |
Biogen Idec Ma Inc. |
Method of isolating biomacromolecules using polyalkylene glycol and transition metals
|
TWI394580B
(zh)
|
2008-04-28 |
2013-05-01 |
Halozyme Inc |
超快起作用胰島素組成物
|
US8932622B2
(en)
*
|
2008-06-03 |
2015-01-13 |
Actamax Surgical Materials, Llc |
Tissue coating for preventing undesired tissue-to-tissue adhesions
|
EP2307367B1
(de)
|
2008-07-08 |
2014-09-24 |
Board of Regents, The University of Texas System |
Neue hemmer der proliferation und aktivierung signalübertragender und transkriptionsaktivierender (stat) proteine
|
US20100015231A1
(en)
*
|
2008-07-17 |
2010-01-21 |
E.I. Du Pont De Nemours And Company |
Low swell, long-lived hydrogel sealant
|
US8551136B2
(en)
|
2008-07-17 |
2013-10-08 |
Actamax Surgical Materials, Llc |
High swell, long-lived hydrogel sealant
|
JP5680534B2
(ja)
|
2008-07-23 |
2015-03-04 |
イーライ リリー アンド カンパニー |
修飾されているウシg−csfポリペプチドおよびそれらの使用
|
UA104146C2
(ru)
*
|
2008-07-31 |
2014-01-10 |
Фармаиссеншиа Корп. |
ПОЛИМЕРНЫЕ КОНЪЮГАТЫ ФРАГМЕНТОВ ИНТЕРФЕРОНА-β, ЭРИТРОПОЭТИНА И ГОРМОНА РОСТА
|
US8716446B2
(en)
*
|
2008-08-25 |
2014-05-06 |
Biopolymed Inc. |
Biopolymer conjugates comprising an interleukin-11 analog
|
PL2342223T3
(pl)
|
2008-09-26 |
2017-09-29 |
Ambrx, Inc. |
Zmodyfikowane polipeptydy zwierzęcej erytropoetyny i ich zastosowania
|
AU2009296267B2
(en)
|
2008-09-26 |
2013-10-31 |
Ambrx, Inc. |
Non-natural amino acid replication-dependent microorganisms and vaccines
|
US8642280B2
(en)
|
2008-11-07 |
2014-02-04 |
Novartis Forschungsstiftung Zweigniederlassung Friedrich Miescher Institute For Biomedical Research |
Teneurin and cancer
|
WO2010059279A2
(en)
*
|
2008-11-19 |
2010-05-27 |
E. I. Du Pont De Nemours And Company |
Hydrogel tissue adhesive formed from aminated polysaccharide and aldehyde-functionalized multi-arm polyether
|
US8466327B2
(en)
|
2008-11-19 |
2013-06-18 |
Actamax Surgical Materials, Llc |
Aldehyde-functionalized polyethers and method of making same
|
TWI496582B
(zh)
|
2008-11-24 |
2015-08-21 |
必治妥美雅史谷比公司 |
雙重專一性之egfr/igfir結合分子
|
CN102307993B
(zh)
|
2008-12-09 |
2014-06-25 |
哈洛齐梅公司 |
延长的可溶性ph20多肽及其用途
|
AR074584A1
(es)
|
2008-12-10 |
2011-01-26 |
Mersana Therapeutics Inc |
Formulaciones farmaceuticas de conjugados camtotecina-polimero biocompatibles biodegradables
|
CA2745443C
(en)
|
2008-12-17 |
2017-02-21 |
Schering Corporation |
Mono- and di-peg il-10 production; and uses
|
US20100160960A1
(en)
*
|
2008-12-19 |
2010-06-24 |
E. I. Du Pont De Nemours And Company |
Hydrogel tissue adhesive having increased degradation time
|
US8716448B2
(en)
|
2009-02-03 |
2014-05-06 |
Amunix Operating Inc. |
Coagulation factor VII compositions and methods of making and using same
|
US20110014190A1
(en)
*
|
2009-02-12 |
2011-01-20 |
Human Genome Sciences, Inc. |
Use of b lymphocyte stimulator protein antagonists to promote transplantation tolerance
|
US20110311521A1
(en)
|
2009-03-06 |
2011-12-22 |
Pico Caroni |
Novel therapy for anxiety
|
EP2405758B1
(de)
*
|
2009-03-09 |
2016-04-27 |
Molecular Express, Inc. |
Verfahren und zusammensetzungen für die liposomale formulierung von antigenen und ihre verwendung
|
US8580732B2
(en)
*
|
2009-04-07 |
2013-11-12 |
Duke University |
Peptide therapy for hyperglycemia
|
EP2416811B1
(de)
|
2009-04-09 |
2015-09-09 |
Actamax Surgical Materials LLC |
Hydrogel-gewebekleber mit verringerter zerfallszeit
|
EP2241323A1
(de)
|
2009-04-14 |
2010-10-20 |
Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research |
Tenascin-W und Hirnkrebs
|
US20100330033A1
(en)
*
|
2009-04-16 |
2010-12-30 |
Nian Wu |
Protein-carrier conjugates
|
AU2010258752B2
(en)
|
2009-06-09 |
2015-07-09 |
Prolong Pharmaceuticals, LLC |
Hemoglobin compositions
|
EP2261662B1
(de)
*
|
2009-06-10 |
2014-01-22 |
Forschungszentrum Borstel Leibniz-Zentrum für Medizin und Biowissenschaften |
Neuartige synthetische Blockierlösungen
|
KR101861547B1
(ko)
|
2009-06-25 |
2018-07-02 |
크레알타 파마슈티칼스 엘엘씨 |
페길화된 유리카아제 치료 중에 혈청 요산을 모니터링하여 주입 반응의 위험성 및 반응의 항체매개 상실을 예측하는 방법 및 키트
|
US8580950B2
(en)
|
2009-07-02 |
2013-11-12 |
Actamax Surgical Materials, Llc |
Aldehyde-functionalized polysaccharides
|
US8778326B2
(en)
|
2009-07-02 |
2014-07-15 |
Actamax Surgical Materials, Llc |
Hydrogel tissue adhesive for medical use
|
US8580951B2
(en)
|
2009-07-02 |
2013-11-12 |
Actamax Surgical Materials, Llc |
Aldehyde-functionalized polysaccharides
|
US8796242B2
(en)
|
2009-07-02 |
2014-08-05 |
Actamax Surgical Materials, Llc |
Hydrogel tissue adhesive for medical use
|
US9663778B2
(en)
|
2009-07-09 |
2017-05-30 |
OPKO Biologies Ltd. |
Long-acting coagulation factors and methods of producing same
|
EP2292266A1
(de)
|
2009-08-27 |
2011-03-09 |
Novartis Forschungsstiftung, Zweigniederlassung |
Behandlung von Krebs durch Modulation von Copine III
|
RU2549986C2
(ru)
|
2009-09-15 |
2015-05-10 |
Канека Корпорейшн |
Модифицированный эритропоэтин, к которому присоединена водорастворимая длинноцепочечная молекула
|
CA2774053C
(en)
|
2009-09-17 |
2015-04-28 |
Baxter Healthcare, S.A. |
Stable co-formulation of hyaluronidase and immunoglobulin, and methods of use thereof
|
WO2011036118A1
(en)
|
2009-09-22 |
2011-03-31 |
Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research |
Treating cancer by modulating mex-3
|
WO2011045352A2
(en)
|
2009-10-15 |
2011-04-21 |
Novartis Forschungsstiftung |
Spleen tyrosine kinase and brain cancers
|
US20120213801A1
(en)
|
2009-10-30 |
2012-08-23 |
Ekaterina Gresko |
Phosphorylated Twist1 and cancer
|
WO2011060233A1
(en)
|
2009-11-11 |
2011-05-19 |
The Trustees Of The University Of Pennsylvania |
Anti-tem1 antibodies and uses thereof
|
WO2011075185A1
(en)
|
2009-12-18 |
2011-06-23 |
Oligasis |
Targeted drug phosphorylcholine polymer conjugates
|
CN107674121A
(zh)
|
2009-12-21 |
2018-02-09 |
Ambrx 公司 |
经过修饰的牛促生长素多肽和其用途
|
CN104017063A
(zh)
|
2009-12-21 |
2014-09-03 |
Ambrx公司 |
经过修饰的猪促生长素多肽和其用途
|
EP2542578A1
(de)
|
2010-03-05 |
2013-01-09 |
Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research |
Smoc1, tenascin-c und hirnkrebs
|
JP6148013B2
(ja)
|
2010-03-05 |
2017-06-14 |
リグショスピタレト |
補体活性化のキメラ抑制分子
|
US20130034543A1
(en)
|
2010-04-19 |
2013-02-07 |
Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Resear |
Modulating xrn1
|
US9018348B2
(en)
|
2010-04-27 |
2015-04-28 |
Agency For Science, Technology And Research |
eIF4E binding peptides
|
US8828181B2
(en)
|
2010-04-30 |
2014-09-09 |
E I Du Pont De Nemours And Company |
Temperature switchable adhesives comprising a crystallizable oil
|
GB201007356D0
(en)
|
2010-04-30 |
2010-06-16 |
Leverton Licence Holdings Ltd |
Conjugated factor VIIa
|
US20120135912A1
(en)
|
2010-05-10 |
2012-05-31 |
Perseid Therapeutics Llc |
Polypeptide inhibitors of vla4
|
EP2580239A1
(de)
|
2010-06-10 |
2013-04-17 |
Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research |
Behandlung von krebs mittels modulation von mammalian-ste20-like-kinase 3
|
JP5825507B2
(ja)
*
|
2010-06-25 |
2015-12-02 |
日油株式会社 |
分岐型ヘテロポリエチレングリコール
|
US10040761B2
(en)
|
2010-06-25 |
2018-08-07 |
Nof Corporation |
Branched hetero polyethylene glycol and intermediate
|
MX348420B
(es)
|
2010-07-20 |
2017-06-12 |
Halozyme Inc |
Efectos secundarios adversos asociados con la administracion de agentes anti-hialuronano y metodos para mejorar o prevenir los efectos secundarios.
|
US8409703B2
(en)
|
2010-07-23 |
2013-04-02 |
E I Du Pont De Nemours And Company |
Temperature switchable adhesive assemblies with temperature non-switchable tack
|
US9567386B2
(en)
|
2010-08-17 |
2017-02-14 |
Ambrx, Inc. |
Therapeutic uses of modified relaxin polypeptides
|
MX346786B
(es)
|
2010-08-17 |
2017-03-31 |
Ambrx Inc |
Polipeptidos de relaxina modificados y sus usos.
|
EP2614080A1
(de)
|
2010-09-10 |
2013-07-17 |
Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research |
Phosphoryliertes twist1 und metastasen
|
AR083006A1
(es)
|
2010-09-23 |
2013-01-23 |
Lilly Co Eli |
Formulaciones para el factor estimulante de colonias de granulocitos (g-csf) bovino y variantes de las mismas
|
US20140093506A1
(en)
|
2010-11-15 |
2014-04-03 |
Marc Buehler |
Anti-fungal-agents
|
JP6190723B2
(ja)
|
2010-12-01 |
2017-08-30 |
アルダーバイオ ホールディングス エルエルシー |
抗ngf組成物およびその使用
|
ES2634669T3
(es)
|
2011-02-08 |
2017-09-28 |
Halozyme, Inc. |
Composición y formulación lipídica de una enzima de degradación de hialuronano y uso de la misma para el tratamiento de la hiperplasia benigna de próstata
|
MX2013009862A
(es)
|
2011-03-02 |
2013-10-25 |
Novo Nordisk As |
Factor de coagulacion dirigido al transcripto 1 tipo trem (tlt-1) en plaquetas activadas.
|
EP2686340A2
(de)
|
2011-03-16 |
2014-01-22 |
Amgen Inc. |
Hochwirksame und selektive inhibitoren von nav1.3 nav1.7
|
CN107827982B
(zh)
|
2011-05-20 |
2021-07-06 |
H.伦德贝克公司 |
抗cgrp抗体和抗体片段用于在有需要的受试者中预防或抑制畏光或厌光的用途
|
SI3495392T1
(sl)
|
2011-05-20 |
2021-11-30 |
H. Lundbeck A/S |
Sestavki proti CGRP in uporaba le-teh
|
AR086515A1
(es)
|
2011-05-20 |
2013-12-18 |
Alderbio Holdings Llc |
Uso de anticuerpos o fragmentos de anticuerpos anti-cgrp o anti-cgrp-r para tratar o prevenir las formas cronicas y agudas de la diarrea
|
US10166295B2
(en)
|
2011-06-02 |
2019-01-01 |
Opko Biologics Ltd. |
Pegylated OXM variants
|
WO2012168259A1
(en)
|
2011-06-06 |
2012-12-13 |
Novartis Forschungsstiftung, Zweigniederlassung |
Protein tyrosine phosphatase, non-receptor type 11 (ptpn11) and triple-negative breast cancer
|
WO2012170969A2
(en)
|
2011-06-10 |
2012-12-13 |
Biogen Idec Ma Inc. |
Pro-coagulant compounds and methods of use thereof
|
EA201400030A1
(ru)
|
2011-06-17 |
2014-07-30 |
Галозим, Инк. |
Способ непрерывного подкожного введения инсулина с использованием фермента, разрушающего хиалуронан
|
US20130011378A1
(en)
|
2011-06-17 |
2013-01-10 |
Tzung-Horng Yang |
Stable formulations of a hyaluronan-degrading enzyme
|
WO2013003593A1
(en)
|
2011-06-28 |
2013-01-03 |
Alternative Innovative Technologies Llc |
Methods of use of hsp70 for increased performance or hsp70 related disorders
|
MX2014000031A
(es)
|
2011-07-01 |
2014-07-09 |
Bayer Ip Gmbh |
Polipeptidos de fusion de relaxina y usos de los mismos.
|
JP6208658B2
(ja)
|
2011-07-05 |
2017-10-04 |
バイオアシス テクノロジーズ インコーポレイテッド |
p97−抗体結合体および使用方法
|
US20130071394A1
(en)
|
2011-09-16 |
2013-03-21 |
John K. Troyer |
Compositions and combinations of organophosphorus bioscavengers and hyaluronan-degrading enzymes, and methods of use
|
WO2013056197A1
(en)
|
2011-10-14 |
2013-04-18 |
Alternative Innovative Technologies Llc |
Degradation resistant hsp70 formulations and uses thereof
|
US8846034B2
(en)
|
2011-10-24 |
2014-09-30 |
Halozyme, Inc. |
Companion diagnostic for anti-hyaluronan agent therapy and methods of use thereof
|
WO2013068431A1
(en)
|
2011-11-08 |
2013-05-16 |
Novartis Forschungsstiftung, Zweigniederlassung, Friedrich Miescher Institute For Biomedical Research |
New treatment for neurodegenerative diseases
|
US20140294732A1
(en)
|
2011-11-08 |
2014-10-02 |
Novartis Forschungsstiftung, Zweigniederlassung, Friedrich Miescher Institute |
Early diagnostic of neurodegenerative diseases
|
RU2685867C2
(ru)
|
2011-12-15 |
2019-04-23 |
Алтернатив Инновейтив Текнолоджиз Ллц |
Гибридные белки и белковые конъюгаты на основе белка теплового шока-70 (БТШ70) и способы их применения (варианты)
|
WO2013102144A2
(en)
|
2011-12-30 |
2013-07-04 |
Halozyme, Inc. |
Ph20 polypeptede variants, formulations and uses thereof
|
US20140363448A1
(en)
|
2012-01-02 |
2014-12-11 |
Novartis Ag |
Cdcp1 and breast cancer
|
NZ626945A
(en)
|
2012-01-12 |
2016-10-28 |
Biogen Ma Inc |
Chimeric factor viii polypeptides and uses thereof
|
CN111548418A
(zh)
|
2012-02-15 |
2020-08-18 |
比奥贝拉蒂治疗公司 |
因子viii组合物及其制备和使用方法
|
KR20190094480A
(ko)
|
2012-02-15 |
2019-08-13 |
바이오버라티브 테라퓨틱스 인크. |
재조합 인자 viii 단백질
|
EP2820150A1
(de)
|
2012-03-01 |
2015-01-07 |
Novo Nordisk A/S |
N-terminus-modifizierte oligopeptide und verwendungen davon
|
US20150266961A1
(en)
|
2012-03-29 |
2015-09-24 |
Novartis Forschungsstiftung, Zweigniederlassung, Fridrich Miescher Institute |
Inhibition of interleukin-8 and/or its receptor cxcr1 in the treatment of her2/her3-overexpressing breast cancer
|
CA2869460C
(en)
|
2012-04-04 |
2018-05-15 |
Halozyme, Inc. |
Combination therapy with an anti-hyaluronan agent and a tumor-targeted taxane
|
CN104487082A
(zh)
|
2012-04-19 |
2015-04-01 |
奥普科生物制品有限公司 |
长效胃泌酸调节素变体及其生产方法
|
US9783610B2
(en)
|
2012-04-27 |
2017-10-10 |
The Trustees Of The University Of Pennsylvania |
Anti-tumor endothelial marker-1 (TEM1) antibody variants and uses thereof
|
JP6262206B2
(ja)
|
2012-05-01 |
2018-01-17 |
ノヴォ ノルディスク アー/エス |
医薬組成物
|
SG10201702228QA
(en)
|
2012-06-04 |
2017-04-27 |
Opko Biolog Ltd |
Pegylated oxm variants
|
AU2013270684B2
(en)
|
2012-06-08 |
2018-04-19 |
Sutro Biopharma, Inc. |
Antibodies comprising site-specific non-natural amino acid residues, methods of their preparation and methods of their use
|
EP2858659B1
(de)
|
2012-06-08 |
2019-12-25 |
Bioverativ Therapeutics Inc. |
Prokoagulationsverbindungen
|
AU2013270683A1
(en)
|
2012-06-08 |
2014-12-11 |
Biogen Ma Inc. |
Chimeric clotting factors
|
GB201210770D0
(en)
*
|
2012-06-18 |
2012-08-01 |
Polytherics Ltd |
Novel conjugation reagents
|
DK2863955T3
(en)
|
2012-06-26 |
2017-01-23 |
Sutro Biopharma Inc |
MODIFIED FC PROTEINS, INCLUDING LOCATION-SPECIFIC NON-NATURAL AMINO ACID RESIDUES, CONJUGATES THEREOF, METHODS OF PRODUCING ITS AND PROCEDURES FOR USE THEREOF
|
US20150218238A1
(en)
|
2012-06-29 |
2015-08-06 |
Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Resear |
Treating diseases by modulating a specific isoform of mkl1
|
US20150184154A1
(en)
|
2012-07-05 |
2015-07-02 |
Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Resear |
New treatment for neurodegenerative diseases
|
PT2882450T
(pt)
|
2012-07-11 |
2020-02-19 |
Bioverativ Therapeutics Inc |
Complexo de fator viii com xten e a proteína fator de von willebrand, e utilizações do mesmo
|
JP6578206B2
(ja)
|
2012-07-19 |
2019-09-18 |
レッドウッド バイオサイエンス, インコーポレイテッド |
Cd22に特異的な抗体およびその使用方法
|
EP2880156B1
(de)
|
2012-07-31 |
2017-08-23 |
biOasis Technologies Inc |
Dephosphorylierte proteine lysosomaler speicherkrankheiten und verwendung davon
|
BR112015003326A2
(pt)
|
2012-08-16 |
2017-07-04 |
Ipierian Inc |
métodos de tratamento de uma tauopatia
|
EP4074728A1
(de)
|
2012-08-31 |
2022-10-19 |
Sutro Biopharma, Inc. |
Modifizierte peptide mit einer azidogruppe
|
US9278124B2
(en)
|
2012-10-16 |
2016-03-08 |
Halozyme, Inc. |
Hypoxia and hyaluronan and markers thereof for diagnosis and monitoring of diseases and conditions and related methods
|
WO2014066744A2
(en)
|
2012-10-25 |
2014-05-01 |
True North Therapeutics, Inc. |
Anti-complement c1s antibodies and uses thereof
|
RS63212B1
(sr)
|
2012-11-02 |
2022-06-30 |
Bioverativ Usa Inc |
Antikomplementna c1s antitela i njihove primene
|
WO2014074218A1
(en)
|
2012-11-12 |
2014-05-15 |
Redwood Bioscience, Inc. |
Compounds and methods for producing a conjugate
|
US9310374B2
(en)
|
2012-11-16 |
2016-04-12 |
Redwood Bioscience, Inc. |
Hydrazinyl-indole compounds and methods for producing a conjugate
|
US9605078B2
(en)
|
2012-11-16 |
2017-03-28 |
The Regents Of The University Of California |
Pictet-Spengler ligation for protein chemical modification
|
US8859705B2
(en)
|
2012-11-19 |
2014-10-14 |
Actamax Surgical Materials Llc |
Hydrogel tissue adhesive having decreased gelation time and decreased degradation time
|
BR122020018510B1
(pt)
|
2012-11-20 |
2023-03-14 |
Opko Biologics Ltd |
Método para aumentar incrementalmente o tamanho hidrodinâmico de um fator de coagulação ativado viia
|
EP2922870B1
(de)
|
2012-11-21 |
2019-08-07 |
The Governors of the University of Alberta |
Immunmodulatorische peptide und verfahren zur verwendung davon
|
JP6426107B2
(ja)
|
2012-12-20 |
2018-11-21 |
アムジエン・インコーポレーテツド |
Apj受容体アゴニストおよびその使用
|
US9675678B2
(en)
|
2013-01-29 |
2017-06-13 |
The Regents Of The University Of Colorado, A Body Corporate |
Compositions and methods for treatment of homocystinuria
|
US9272075B2
(en)
|
2013-02-04 |
2016-03-01 |
W.L. Gore & Associates, Inc. |
Coating for substrate
|
ES2692150T3
(es)
|
2013-02-04 |
2018-11-30 |
W.L. Gore & Associates, Inc. |
Revestimiento para sustrato
|
TW201446792A
(zh)
|
2013-03-12 |
2014-12-16 |
Amgen Inc |
Nav1.7之強效及選擇性抑制劑
|
CN105263958B
(zh)
|
2013-03-13 |
2019-09-27 |
比奥阿赛斯技术有限公司 |
p97片段及其应用
|
CA2905484C
(en)
|
2013-03-14 |
2020-07-21 |
Alere San Diego, Inc. |
6-acetylmorphine analogs, and methods for their synthesis and use
|
CN105209497B
(zh)
|
2013-03-15 |
2021-09-07 |
诺和诺德股份有限公司 |
能够特异性结合组织因子途径抑制物上的两个表位的抗体
|
US9458292B2
(en)
|
2013-03-27 |
2016-10-04 |
Nof Corporation |
Method for purifying polyethylene glycol having one amino group
|
RU2679889C2
(ru)
|
2013-04-18 |
2019-02-14 |
Армо Байосайенсиз, Инк. |
Способы применения интерлейкина-10 для лечения заболеваний и расстройств
|
WO2014176309A1
(en)
|
2013-04-23 |
2014-10-30 |
Nizyme, Inc. |
Methods and compositions for treating diseases
|
ES2800827T3
(es)
|
2013-06-10 |
2021-01-04 |
Ipierian Inc |
Procedimientos de tratamiento de una tauopatía
|
CA2914837A1
(en)
|
2013-06-17 |
2014-12-24 |
Armo Biosciences, Inc. |
Method for assessing protein identity and stability
|
TW201534726A
(zh)
|
2013-07-03 |
2015-09-16 |
Halozyme Inc |
熱穩定ph20玻尿酸酶變異體及其用途
|
CA2916980C
(en)
|
2013-07-03 |
2023-02-21 |
Alder Biopharmaceuticals, Inc. |
Regulation of glucose metabolism using anti-cgrp antibodies
|
ES2865473T3
(es)
|
2013-07-10 |
2021-10-15 |
Sutro Biopharma Inc |
Anticuerpos que comprenden múltiples residuos de aminoácidos no naturales sitio-específicos, métodos para su preparación y métodos de uso
|
EP3027659B1
(de)
|
2013-07-29 |
2020-12-09 |
Actamax Surgical Materials LLC |
Gewebeklebstoff mit niedriger schwellung und dichtungsmittelzusammensetzungen
|
ES2761587T3
(es)
|
2013-08-07 |
2020-05-20 |
Friedrich Miescher Institute For Biomedical Res |
Nuevo método de cribado para el tratamiento de la ataxia de Friedreich
|
TW202003554A
(zh)
|
2013-08-14 |
2020-01-16 |
美商百歐維拉提夫治療公司 |
因子viii-xten融合物及其用途
|
EP3038657A2
(de)
|
2013-08-28 |
2016-07-06 |
Bioasis Technologies Inc. |
Cns-gerichtete konjugate mit modifizierten fc-regionen und verfahren zur verwendung davon
|
US10010588B2
(en)
|
2013-08-30 |
2018-07-03 |
Armo Biosciences, Inc. |
Methods of using pegylated interleukin-10 for treating hyperlipidemia
|
JP6463361B2
(ja)
|
2013-09-08 |
2019-01-30 |
コディアック サイエンシーズ インコーポレイテッドKodiak Sciences Inc. |
第viii因子両性イオンポリマーコンジュゲート
|
EP3903599A1
(de)
|
2013-09-25 |
2021-11-03 |
Bioverativ Therapeutics Inc. |
Verfahren zur virusinaktivierung auf einer säule
|
WO2015054658A1
(en)
|
2013-10-11 |
2015-04-16 |
Sutro Biopharma, Inc. |
Modified amino acids comprising tetrazine functional groups, methods of preparation, and methods of their use
|
US20150158926A1
(en)
|
2013-10-21 |
2015-06-11 |
Opko Biologics, Ltd. |
Long-acting polypeptides and methods of producing and administering same
|
WO2015070014A1
(en)
|
2013-11-08 |
2015-05-14 |
Biogen Idec Ma Inc. |
Procoagulant fusion compound
|
WO2015070060A1
(en)
|
2013-11-11 |
2015-05-14 |
Armo Biosciences, Inc. |
Methods of using interleukin-10 for treating diseases and disorders
|
EP3074420A2
(de)
|
2013-11-27 |
2016-10-05 |
Ipierian, Inc. |
Verfahren zur behandlung einer tauopathie
|
US9493413B2
(en)
|
2013-11-27 |
2016-11-15 |
Redwood Bioscience, Inc. |
Hydrazinyl-pyrrolo compounds and methods for producing a conjugate
|
SI3091997T1
(sl)
|
2014-01-10 |
2022-10-28 |
Bioverativ Therapeutics Inc. |
Himerni proteini faktorja VIII in njihova uporaba
|
CN106573072A
(zh)
|
2014-06-02 |
2017-04-19 |
阿尔莫生物科技股份有限公司 |
降低血清胆固醇的方法
|
EP4257152A3
(de)
|
2014-06-10 |
2023-12-06 |
Amgen Inc. |
Apelinpolypeptide
|
US20170137824A1
(en)
|
2014-06-13 |
2017-05-18 |
Indranil BANERJEE |
New treatment against influenza virus
|
EP3157535A1
(de)
|
2014-06-23 |
2017-04-26 |
Friedrich Miescher Institute for Biomedical Research |
Verfahren zur auslösung der novo-bildung von heterochromatin und/oder zur epigenetischen abschaltung mit kleinen rnas
|
PL3186281T3
(pl)
|
2014-08-28 |
2019-10-31 |
Halozyme Inc |
Terapia skojarzona enzymem rozkładającym hialuronian i inhibitorem punktu kontrolnego odpowiedzi immunologicznej
|
WO2016046768A1
(en)
|
2014-09-24 |
2016-03-31 |
Friedrich Miescher Institute For Biomedical Research |
Lats and breast cancer
|
EP3197481A1
(de)
|
2014-09-26 |
2017-08-02 |
Bayer Pharma Aktiengesellschaft |
Stabilisierte adrenomedullinderivate und verwendung davon
|
PL3207130T3
(pl)
|
2014-10-14 |
2020-02-28 |
Halozyme, Inc. |
Kompozycje deaminazy adenozyny 2 (ada2), jej warianty i sposoby ich zastosowania
|
EP3206713A4
(de)
|
2014-10-14 |
2018-06-27 |
Armo Biosciences, Inc. |
Interleukin-15-zusammensetzungen und verwendungen davon
|
CN107106655A
(zh)
|
2014-10-22 |
2017-08-29 |
阿尔莫生物科技股份有限公司 |
使用白细胞介素‑10治疗疾病和病症的方法
|
MA40835A
(fr)
|
2014-10-23 |
2017-08-29 |
Biogen Ma Inc |
Anticorps anti-gpiib/iiia et leurs utilisations
|
IL251834B2
(en)
|
2014-10-23 |
2023-09-01 |
Ngm Biopharmaceuticals Inc |
Pharmaceutical compositions containing peptide variants and methods of using them
|
KR102637699B1
(ko)
|
2014-10-24 |
2024-02-19 |
브리스톨-마이어스 스큅 컴퍼니 |
변형된 fgf-21 폴리펩티드 및 그의 용도
|
MA40861A
(fr)
|
2014-10-31 |
2017-09-05 |
Biogen Ma Inc |
Anticorps anti-glycoprotéines iib/iiia
|
PL3215193T3
(pl)
|
2014-11-06 |
2024-03-18 |
Pharmaessentia Corporation |
Reżim podawania pegylowanego interferonu
|
TWI686401B
(zh)
|
2014-11-19 |
2020-03-01 |
英商Nzp英國有限公司 |
化合物(三)
|
CA2968301C
(en)
|
2014-11-19 |
2023-05-16 |
NZP UK Limited |
5.beta.-6-alkyl-7-hydroxy-3-one steroids as intermediates for the production of steroidal fxr modulators
|
WO2016079520A1
(en)
|
2014-11-19 |
2016-05-26 |
Dextra Laboratories Limited |
6.alpha.-alkyl-6,7-dione steroids as intermediates for the production of steroidal fxr modulators
|
CA2968309A1
(en)
|
2014-11-19 |
2016-05-26 |
NZP UK Limited |
6-alkyl-7-hydroxy-4-en-3-one steroids as intermediates for the production of steroidal fxr modulators
|
ES2848376T3
(es)
|
2014-11-19 |
2021-08-09 |
Axon Neuroscience Se |
Anticuerpos de tau humanizados en la enfermedad de Alzheimer
|
EP3233916A4
(de)
|
2014-12-19 |
2018-06-06 |
Alder Biopharmaceuticals, Inc. |
Humanisierte anti-acth-antikörper und verwendungen davon
|
WO2016126615A1
(en)
|
2015-02-03 |
2016-08-11 |
Armo Biosciences, Inc. |
Methods of using interleukin-10 for treating diseases and disorders
|
CN115919996A
(zh)
|
2015-05-01 |
2023-04-07 |
雅利斯塔制药公司 |
用于治疗眼科疾病的脂联素拟肽
|
EP3302547A1
(de)
|
2015-05-28 |
2018-04-11 |
Armo Biosciences, Inc. |
Pegyliertes interleukin-10 zur behandlung von krebs
|
EP3302528A1
(de)
|
2015-05-29 |
2018-04-11 |
Armo Biosciences, Inc. |
Verfahren zur verwendung von interleukin-10 zur behandlung von erkrankungen und leiden
|
AU2016273045B2
(en)
|
2015-05-29 |
2020-11-26 |
Opko Biologics Ltd. |
Pegylated oxyntomodulin variants
|
JP6921006B2
(ja)
|
2015-06-15 |
2021-08-18 |
ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー |
老化関連症状を治療するための方法および組成物
|
WO2016203482A2
(en)
|
2015-06-19 |
2016-12-22 |
Opko Biologics Ltd. |
Long-acting coagulation factors and methods of producing same
|
JP6909203B2
(ja)
|
2015-08-03 |
2021-07-28 |
バイオベラティブ セラピューティクス インコーポレイテッド |
第ix因子融合タンパク質及びそれらの製造方法及び使用方法
|
CA2994971A1
(en)
|
2015-08-12 |
2017-02-16 |
Cell Machines, Inc. |
Methods and compositions related to long half-life coagulation complexes
|
AU2016312510A1
(en)
|
2015-08-25 |
2018-03-08 |
Armo Biosciences, Inc. |
Methods of using Interleukin-10 for treating diseases and disorders
|
KR20180042412A
(ko)
|
2015-09-02 |
2018-04-25 |
이뮤텝 에스.에이.에스. |
항-lag-3 항체
|
US10449259B2
(en)
|
2015-10-02 |
2019-10-22 |
Cornell University |
Enzyme-responsive peptide nanofiber compositions and uses thereof
|
WO2017072669A1
(en)
|
2015-10-28 |
2017-05-04 |
Friedrich Miescher Institute For Biomedical Research |
Tenascin-w and biliary tract cancers
|
CA3003616C
(en)
|
2015-11-09 |
2020-07-28 |
Ngm Biopharmaceuticals, Inc. |
Methods for treatment of bile acid-related disorders
|
IL302198A
(en)
|
2015-11-09 |
2023-06-01 |
Univ Colorado Regents |
Preparations and methods for the treatment of excessive homocysteine in the urine
|
EP3407917A1
(de)
|
2016-01-27 |
2018-12-05 |
Sutro Biopharma, Inc. |
Anti-cd74-antikörperkonjukate, zusammensetzungen mit anti-cd74-antikörperkonjugaten und verfahren zur verwendung von anti-cd74-antikörperkonjugaten
|
WO2017160599A1
(en)
|
2016-03-14 |
2017-09-21 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Use of cd300b antagonists to treat sepsis and septic shock
|
KR20190003951A
(ko)
|
2016-04-04 |
2019-01-10 |
바이오버라티브 유에스에이 인코포레이티드 |
항-보체 인자 bb 항체 및 이의 용도
|
WO2017181031A2
(en)
|
2016-04-15 |
2017-10-19 |
Alder Biopharmaceuticals, Inc. |
Anti-pacap antibodies and uses thereof
|
AU2017267728B2
(en)
|
2016-05-18 |
2021-11-04 |
Alere San Diego, Inc. |
2-ethylidene-1,5-dimethyl-3,3-diphenylpyrrolidine analogs and methods for their synthesis and use
|
GB201608777D0
(en)
|
2016-05-18 |
2016-06-29 |
Dextra Lab Ltd |
Compounds
|
GB201608776D0
(en)
|
2016-05-18 |
2016-06-29 |
Dextra Lab Ltd |
Methods and compounds
|
WO2017212494A1
(en)
|
2016-06-09 |
2017-12-14 |
Opko Biologics Ltd. |
Long-acting oxyntomodulin formulation and methods of producing and administering same
|
HUE064463T2
(hu)
|
2016-07-11 |
2024-03-28 |
Opko Biologics Ltd |
Hosszantartó hatású VII. koagulációs faktor és az elõállítására vonatkozó eljárások
|
EP3529615A1
(de)
|
2016-10-24 |
2019-08-28 |
Novo Nordisk A/S |
Bioassay für insulinformulierungen
|
KR20220147720A
(ko)
|
2016-11-14 |
2022-11-03 |
항저우 디에이씨 바이오테크 씨오, 엘티디 |
결합 링커, 그러한 결합 링커를 함유하는 세포 결합 분자-약물 결합체, 링커를 갖는 그러한 결합체의 제조 및 사용
|
US11135307B2
(en)
|
2016-11-23 |
2021-10-05 |
Mersana Therapeutics, Inc. |
Peptide-containing linkers for antibody-drug conjugates
|
EP3562840A1
(de)
|
2016-12-16 |
2019-11-06 |
Biogen MA Inc. |
Stabilisierter proteolytisch aktivierter wachstumsdifferenzierungsfaktor 11
|
SG11201907209QA
(en)
|
2017-02-08 |
2019-09-27 |
Bristol Myers Squibb Co |
Modified relaxin polypeptides comprising a pharmacokinetic enhancer and uses thereof
|
JP6935059B2
(ja)
|
2017-03-30 |
2021-09-15 |
日油株式会社 |
カルボキシル基を一つ有するポリエチレングリコールの精製方法
|
WO2018195006A1
(en)
|
2017-04-17 |
2018-10-25 |
The Regents Of The University Of Colorado, A Body Corporate |
Optimization of enzyme replacement therapy for treatment of homocystinuria
|
WO2018231706A1
(en)
|
2017-06-11 |
2018-12-20 |
Molecular Express, Inc. |
Methods and compositions for substance use disorder vaccine formulations and uses thereof
|
US10781435B2
(en)
|
2017-06-22 |
2020-09-22 |
Catalyst Biosciences, Inc. |
Modified membrane type serine protease 1 (MTSP-1) polypeptides and methods of use
|
EP3658588A1
(de)
|
2017-07-26 |
2020-06-03 |
Sutro Biopharma, Inc. |
Verfahren zur verwendung von anti-cd74-antikörpern und antikörperkonjugaten bei der behandlung von t-zell-lymphomen
|
WO2019030692A1
(en)
|
2017-08-10 |
2019-02-14 |
Friedrich Miescher Institute For Biomedical Research |
HDAC6 AND AGGREGATION OF PROTEINS
|
US10596270B2
(en)
|
2017-09-18 |
2020-03-24 |
Sutro Biopharma, Inc. |
Anti-folate receptor antibody conjugates, compositions comprising anti-folate receptor antibody conjugates, and methods of making and using anti-folate receptor antibody conjugates
|
US20200353050A1
(en)
|
2017-11-10 |
2020-11-12 |
Armo Biosciences, Inc. |
Compositions and methods of use of interleukin-10 in combination with immune check-point pathway inhibitors
|
CN111094462A
(zh)
|
2017-12-26 |
2020-05-01 |
贝克顿·迪金森公司 |
深紫外线可激发的水溶剂化聚合物染料
|
MX2020009975A
(es)
|
2018-03-28 |
2020-10-12 |
Bristol Myers Squibb Co |
Proteinas de fusion interleucina-2/receptor alfa de interleucina-2 y metodos de uso.
|
US10844228B2
(en)
|
2018-03-30 |
2020-11-24 |
Becton, Dickinson And Company |
Water-soluble polymeric dyes having pendant chromophores
|
WO2019211842A1
(en)
|
2018-04-30 |
2019-11-07 |
Opko Biologics Ltd. |
Long-acting human growth hormone-antagonists and methods of producing the same
|
WO2019222435A1
(en)
|
2018-05-16 |
2019-11-21 |
Halozyme, Inc. |
Methods of selecting subjects for combination cancer therapy with a polymer-conjugated soluble ph20
|
EP3810189A1
(de)
|
2018-06-19 |
2021-04-28 |
Armo Biosciences, Inc. |
Zusammensetzungen und verfahren zur verwendung von il-10-wirkstoffen in verbindung mit einer chimären antigen-rezeptor-zelltherapie
|
PE20210632A1
(es)
|
2018-07-03 |
2021-03-23 |
Bristol Myers Squibb Co |
Formulaciones de fgf-21
|
WO2020023300A1
(en)
|
2018-07-22 |
2020-01-30 |
Bioasis Technologies, Inc. |
Treatment of lymmphatic metastases
|
PL3849614T3
(pl)
|
2018-09-11 |
2024-04-22 |
Ambrx, Inc. |
Koniugaty polipeptydu interleukiny-2 i ich zastosowania
|
JP2022500454A
(ja)
|
2018-09-17 |
2022-01-04 |
ストロ バイオファーマ インコーポレーテッド |
抗葉酸受容体抗体コンジュゲートによる併用療法
|
CN113366015A
(zh)
|
2018-10-19 |
2021-09-07 |
Ambrx公司 |
白细胞介素-10多肽缀合物、其二聚体及其用途
|
US11613744B2
(en)
|
2018-12-28 |
2023-03-28 |
Vertex Pharmaceuticals Incorporated |
Modified urokinase-type plasminogen activator polypeptides and methods of use
|
CN113661239A
(zh)
|
2018-12-28 |
2021-11-16 |
催化剂生物科学公司 |
经修饰的尿激酶型纤溶酶原激活物多肽和使用方法
|
CN113710692A
(zh)
|
2019-02-11 |
2021-11-26 |
Opko生物科学有限公司 |
长效glp-2类似物
|
EP3923991A1
(de)
|
2019-02-12 |
2021-12-22 |
Ambrx, Inc. |
Zusammensetzungen mit sowie verfahren und verwendungen von antikörper-tlr-agonist-konjugaten
|
US20220362394A1
(en)
|
2019-05-03 |
2022-11-17 |
Sutro Biopharma, Inc. |
Anti-bcma antibody conjugates
|
CN114269749A
(zh)
|
2019-06-10 |
2022-04-01 |
苏特罗生物制药公司 |
5H-吡咯并[3,2-d]嘧啶-2,4-二氨基化合物及其抗体偶联物
|
CN114746420A
(zh)
|
2019-06-17 |
2022-07-12 |
苏特罗生物制药公司 |
用于癌症治疗和诊断的作为Toll样受体(TLR)7/8激动剂的1-(4-(氨基甲基)苄基)-2-丁基-2H-吡唑并[3,4-c]喹啉-4-胺衍生物及相关化合物以及其抗体药物偶联物
|
EP3986918A1
(de)
|
2019-06-18 |
2022-04-27 |
Bayer Aktiengesellschaft |
Adrenomedullin-analoga zur langzeitstabilisierung und ihre verwendung
|
CA3152665A1
(en)
|
2019-08-27 |
2021-03-04 |
Tonix Pharma Limited |
Modified tff2 polypeptides
|
CN114786731A
(zh)
|
2019-10-10 |
2022-07-22 |
科达制药股份有限公司 |
治疗眼部病症的方法
|
BR112022013172A2
(pt)
|
2020-01-08 |
2022-09-13 |
Bristol Myers Squibb Co |
Formulações de conjugados de fgf-21
|
US20230095053A1
(en)
|
2020-03-03 |
2023-03-30 |
Sutro Biopharma, Inc. |
Antibodies comprising site-specific glutamine tags, methods of their preparation and methods of their use
|
AU2021233909A1
(en)
|
2020-03-11 |
2022-09-29 |
Ambrx, Inc. |
Interleukin-2 polypeptide conjugates and methods of use thereof
|
BR102020007149A8
(pt)
|
2020-04-06 |
2023-09-26 |
H Lundbeck As |
Usos de um anticorpo anti-cgrp ou anti-cgrp-r ou um fragmento dos mesmos para melhorar o sintoma mais incômodo (mbs) e a impressão global de mudança (pgic) associados com enxaqueca
|
EP4143227A2
(de)
|
2020-04-30 |
2023-03-08 |
Sairopa B.V. |
Anti-cd103 antikörper
|
US20210355468A1
(en)
|
2020-05-18 |
2021-11-18 |
Bioasis Technologies, Inc. |
Compositions and methods for treating lewy body dementia
|
US20210393787A1
(en)
|
2020-06-17 |
2021-12-23 |
Bioasis Technologies, Inc. |
Compositions and methods for treating frontotemporal dementia
|
JP2023538533A
(ja)
|
2020-08-07 |
2023-09-08 |
ブリストル-マイヤーズ スクイブ カンパニー |
線維症の処置のための、ccr2/5拮抗剤と組み合わせたfgf21
|
EP3954393A1
(de)
|
2020-08-13 |
2022-02-16 |
Bioasis Technologies Inc. |
Kombinationstherapien zur verabreichung über die blut-hirn-schranke hinweg
|
KR20230073200A
(ko)
|
2020-08-20 |
2023-05-25 |
암브룩스, 인코포레이티드 |
항체-tlr 작용제 접합체, 그 방법 및 용도
|
WO2022103983A2
(en)
|
2020-11-11 |
2022-05-19 |
Sutro Biopharma, Inc. |
Fluorenylmethyloxycarbonyl and fluorenylmethylaminocarbonyl compounds, protein conjugates thereof, and methods for their use
|
WO2022115597A1
(en)
|
2020-11-25 |
2022-06-02 |
Bristol-Myers Squibb Company |
Methods of treating liver diseases
|
JP2024512775A
(ja)
|
2021-04-03 |
2024-03-19 |
アンブルックス,インコーポレイテッド |
抗her2抗体薬物コンジュゲート及びその使用
|
AR125490A1
(es)
|
2021-04-30 |
2023-07-19 |
Celgene Corp |
Terapias de combinación que utilizan un anticuerpo anti-bcma conjugado a fármaco (adc) en combinación con un inhibidor de gamma secretasa (gsi)
|
CN117957021A
(zh)
|
2021-08-20 |
2024-04-30 |
拜耳公司 |
用于制备聚乙二醇化肾上腺髓质素的方法、它的中间体及其用途
|
KR20240049275A
(ko)
|
2021-08-27 |
2024-04-16 |
하. 룬드벡 아크티에셀스카브 |
항-cgrp 항체를 사용한 군발성 두통의 치료
|
EP4155349A1
(de)
|
2021-09-24 |
2023-03-29 |
Becton, Dickinson and Company |
Wasserlösliche gelbe grünabsorbierende farbstoffe
|
US20240091365A1
(en)
|
2022-06-27 |
2024-03-21 |
Sutro Biopharma, Inc. |
Beta-glucuronide linker-payloads, protein conjugates thereof, and methods thereof
|
US20240058465A1
(en)
|
2022-06-30 |
2024-02-22 |
Sutro Biopharma, Inc. |
Anti-ror1 antibody conjugates, compositions comprising anti ror1 antibody conjugates, and methods of making and using anti-ror1 antibody conjugates
|
WO2024007016A2
(en)
|
2022-07-01 |
2024-01-04 |
Beckman Coulter, Inc. |
Novel fluorescent dyes and polymers from dihydrophenanthrene derivatives
|
WO2024015229A1
(en)
|
2022-07-15 |
2024-01-18 |
Sutro Biopharma, Inc. |
Protease/enzyme cleavable linker-payloads and protein conjugates
|
WO2024044327A1
(en)
|
2022-08-26 |
2024-02-29 |
Beckman Coulter, Inc. |
Dhnt monomers and polymer dyes with modified photophysical properties
|
WO2024044780A1
(en)
|
2022-08-26 |
2024-02-29 |
Sutro Biopharma, Inc. |
Interleukin-18 variants and uses thereof
|